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1. INTRODUCTION 
 
Drugs can be administered through different routes. However, of all the routes 
of administration, oral route of administration is the most convenient for 
administering drugs for systemic effect because of ease of administration, 
manufacturing and dosage adjustments. Parentral route is not routinely used because 
of difficulty in self administration and hence hospitalization may be required. Topical 
route is recently developed and is employed for only few drugs like Nitroglycerine, 
Scopolamine for systemic effect. Topical route has limitations in its ability to allow 
effective drug absorption for systemic drug action. Parentral administration is 
employed in the case of emergency and in which the subject is comatose or cannot 
swallow. Nevertheless it is possible that at least 90% of all drugs used to produce 
systemic effect are administered by oral route. 
 
           Oral route of drug administration has wide acceptance and of the drugs 
administered orally in solid dosage forms represents the preferred class of products. 
The reasons are, Tablets and capsules represent unit dosage form in which one usual 
dose of drug has been accurately placed. 
 
           By comparison liquid oral dosage forms such as syrups, suspensions, 
emulsions, solutions, and elixirs are usually designed to contain one dose medication 
in 5-30ml. Such dosage measurements are typically error by a factor ranging from 20-
50% when the drug is self administered by patient. Liquid oral dosage forms have 
other disadvantages and limitations1. 
     
1.1. TABLETS:  
Tablets are defined as solid preparations each containing a single dose of one 
or more active ingredients and obtained by compressing uniform volumes of particles. 
They are intended for oral administration, some are swallowed whole, some after 
being chewed. Some are dissolved or dispersed in water before being administered 
and some are retained in the mouth, where the active ingredients are liberated. Tablets 
are used mainly for systemic drug delivery but also for local drug action. For systemic 
use drug must be released from tablet that is dissolved in the fluids of mouth, stomach 
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and intestine and then absorbed into systemic circulation by which it reaches its site of 
action. 
 
1.2. ADVANTAGES OF TABLETS2: 
1. They are unit dosage forms and have dose precision and least content 
variability. 
2. Their cost is less. 
3. Product identification is potentially the simplest and cheapest and greatest ease 
of Swallowing. 
4. They have the best combined properties of chemical, mechanical and micro 
biological stability of all the oral dosage forms. 
 
1.3. PROPERITES OF TABLETS: 
A Tablet 
1. Should be an elegant product, free of defects such as chips, cracks and                        
discoloration. 
2. Should have the strength to withstand the rigors of mechanical shocks 
encountered in its production, packaging, shipping and dispensing.  
3. Should have physical and chemical stability. 
4. Must be able to release the medicinal agent in the body in a predictable and      
reproducible manner. 
 
1.4. TABLET DESIGN AND FORMULATION3:  
Compressed tablets may be made by three basic methods. 
      1.4.1 Wet granulation 
      1.4.2 Direct compression 
      1.4.3 Slugging (Dry granulation) 
 
1.4.1. Wet granulation 
Wet granulation is a process of using a liquid binder or adhesive to the powder 
mixture. The amount of liquid can be properly managed and over wetting will cause 
the granules to be too hard and under wetting will cause the granules to be too soft 
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and friable. Aqueous solutions have the advantage of being safer to deal with than 
other solvents. 
Procedure of Wet Granulation  
Step 1: Weighing and Blending - the active ingredient, filler, disintegration agents are 
weighed and mixed. 
Step 2: The wet granulate is prepared by adding the liquid binder/adhesive. Examples      
of binders/adhesives include aqueous preparations of cornstarch, natural gums 
such as acacia, cellulose derivatives such as methyl cellulose, CMC, gelatin, 
and povidone. Ingredients are placed within a granulator which helps ensure 
correct density of the composition.  
Step 3: Screening the damp mass into pellets or granules.  
Step 4: Drying the granules. 
Step 5: Dry screening: After the granules are dried, pass through a screen of smaller 
size than the one used for the wet mass to select granules of uniform size to 
allow even fill in the die cavity. 
Step 6: Lubrication- A dry lubricant, antiadherent and glidant are added to the 
granules either by dusting over the spread-out granules or by blending with the 
granules. It reduces the friction between the tablet and the walls of the die 
cavity. Antiadherents  reduce sticking of the tablet to the die and punch. 
Step 7: Tableting: Last step in which the tablet is fed into the die cavity and then 
compressed between a lower and an upper punch.   
 
Water may be used as the liquid binder, but sometimes many actives are not 
compatible with water. Water mixed into the powder can form bonds between powder 
particles that are strong enough to lock them in together. However, once the water 
dries, the powders may fall apart and therefore might not be strong enough to create 
and hold a bond. Povidone also known as polyvinyl pyrrolidone (PVP) is one of the 
most commonly used pharmaceutical binders. PVP and a solvent are mixed with the 
powders to form a bond during the process, and the  solvent evaporates. Once the 
solvent evaporates and powders have formed a densely held mass, then the 
granulation is milled which results in formation of granules.  
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Advantages of wet granulation: 
1. The cohesiveness and compressibility of powders is improved due to the                       
added binder that coats the individual powder particles causing them to adhere 
to each other so they can be formed into agglomerates called granules. Drugs 
having a high dosage and poor flow must be granulated by the wet granulation 
method to obtain suitable flow and cohesion for compression. 
2. Good distribution and uniform content for the soluble low dosage drugs and 
color additives are obtained if these are dissolved in binder solution. 
3. Wet granulation prevents segregation of components of a homogenous powder 
mixture during processing, transferring, and handling. 
4. The dissolution rate of an insoluble drug may be improved by wet granulation. 
5. Controlled release dosage forms can be accomplished by the selection of 
suitable    solvents. 
 
Limitations of wet granulation 
1. This method is very costly because of space, time and equipment involved. 
2. The process is labour intensive because of large number of processing steps, 
number of pieces of extensive equipment.  
3. It is time consuming, especially the wetting and drying steps. 
4. Material loss during processing due to transfer of material from, one unit 
operation to another. 
 
1.4.2. Dry granulation 
This process is used when the product needed to be granulated may be 
sensitive to moisture and heat. Dry granulation can be conducted on a press using 
slugging tooling or on a roller compactor commonly referred to as a chilsonator. Dry 
granulation equipment offers a wide range of pressure and roll types to attain proper 
densification. However, the process may require repeated compaction steps to attain 
the proper granule end point. 
 
Process times are often reduced and equipment requirements are streamlined; 
therefore the cost is reduced. However, dry granulation often produces a higher 
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percentage of fines or non compacted products, which could compromise the quality 
or create yield problems for the tablet. It requires drugs or excipients with cohesive 
properties. 
1. Some granular chemicals are suitable for direct compression (free  flowing) 
e.g. potassium chloride.  
2. Tablet excipients with good flow characteristics and compressibility allow for 
direct compression of a variety of drugs. 
1.4.3. Slugging: 
In this method, after weighing and mixing the ingredients, the powder mixture 
is “slugged” or compressed into large flat tablets or pellets of about 1 inch in 
diameter. The slugs then are broken up by a mill and passed through a screen of 
desired mesh for sizing. Lubricant is added in the usual manner, and tablets are 
prepared by compression. Aspirin, which is hydrolyzed on exposure to moisture, may 
be prepared into tablets after slugging. 
 
1.5. FORMULATION TECHNIQUES4 
Generally dispersible tablets are formulated by conventional techniques like 
direct compression technology, wet granulation and slugging process. 
 
1.5.1. Factors to be considered in formulation development 
The Success of formulations by direct compression depends on careful 
consideration of excipient properties and optimization of the compressibility, fluidity 
and lubricating ability of power blends. 
 
1.6. COMPRESSIBILITY  
Formulation should be direct at optimizing tablet hardness without applying 
excessive compression force while at the same time assuring rapid tablet 
disintegration and drug dissolution. In those cases where the drug makes up the 
greater part of final tablet weight, the functional properties of active ingredient, type 
and concentration of excipient dominate the problem. 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 6 
 
In regard to the active ingredients it is important to determine the effect of 
particle size on compressibility as well as the effect of crystalline form on 
compressibility and density. 
 
The most effective dry binder is microcrystalline cellulose. It can add 
significant hardness of 3-5% it is considered in tablet formulation when the hardness 
or friability is a problem. Almost all disintegrating agents retard compressibility as 
well as fluidity due to particle size for optimal disintegration, particle size of 
disintegrating agent is small.   
 
Generally direct compression formulation is less compressible than wet 
granulation. 
   
1.7. FLUIDITY: 
The fluidity of tablet blends is important not only from the direct effect on 
uniformity of die fill and thus uniformity of tablet weight, but also from the role it 
plays in blending and power homogeneity. 
 
Fluidity of active ingredients becomes a factor when the drug has been 
micronized to improve dissolution rate. 
 
In order to design tablet machine with high output more sophisticated feeders 
with adequate contact of feeder with die cavity to allow uniform filling. There are two 
basic approaches to increasing die-feeding efficiency. 
 
a. To force material into die cavity. 
b. To improve flow properties of material directly above the die cavity. 
 
 1.8. CONTENT UNIFORMITY: 
Highly fluid powder blends facilitate unblending. The narrower the particle 
size range of all components and the more alike the particles densities, the less chance 
for unblending or segregation. 
 
Major problem with segregation can occur in spherically shaped fillers, if the 
particle is large and spherical, such as in the case with compressible dextrose. 
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It is theorized that blending of all materials at once would have interfered with 
the surface attraction of drug particles to filler and resulted in decreased homogeneity. 
 
1.9. LUBRICATION: 
The problem associated with lubricating direct compression blends are 
1. Type and amount needed to produce adequate lubrication. 
2. The softening effect of lubrication. 
 
 The small particle size of lubricants in granulation is of great importance in 
direct compression. Even when all surfaces of granules are covered by a layer of 
lubricant, clean surfaces are formed during compression. Standard blending times will 
results in complete coverage of these surfaces. 
 
 The lengths of blending become much more critical in direct compression than 
in lubrication of tablet granulation. 
 
 Ejection force, hardness, disintegration and dissolution of all directly 
compressed tablets of lactose and microcrystalline cellulose where all significantly 
affected by blending times. 
 
1.10. STUDY OF PHYSICOCHEMICAL TABLETING PROPERTIES OF 
DRUG: 
The formulation of tablets is governed by a number of factors like  particle  
size, size frequency, bulk density, compressibility, flow ability, porosity, moisture 
content, solubility and melting point. Influences of particle size on dissolution rate, 
study of compacts of the drug in order to compress the tablet directly are important. 
 
1.10.1. Powder characteristics: 
 A number of empirical studies exist in the pharmaceutical literature with the 
aim of mapping factors that affects the structure of tablet and its mechanical strength, 
i.e. tensile strength, resistance towards attrition and capping tendencies. These factors 
can be classified into three groups. 
 
1) Material and formulation factors 
2) Processing factors 
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3) Environmental factors 
        
Of special importance from a formulation perspective are the physical and 
mechanical properties of the particles used in the formulation and how these particles 
are combined in granulation and mixing steps. 
 
1.10.2. Flow properties5:  
The flow properties of a powder result from many forces. Solid particles when 
they are in contact are predominantly surface forces. Many types of forces act 
between solid particles they are 
 
a) Frictional force 
b) Surface tension forces 
c) Mechanical forces caused by interlocking of particles of irregular shape. 
d) Electrostatic forces. 
e) Cohesive or vanderwaal’s force. 
 
 All these forces can affect flow properties of a solid. They can also effect 
granule properties such as particle size, particle size distribution, particle shape, 
surface texture or roughness, residual surface energy and surface area. 
 
The test to determine flow rate are two types 
1. Direct methods 
a) Hopper flow method 
b) Recording flow meter method 
2. Indirect methods 
a. Determination of angle of repose 
b. Measurement of bulk density and compressibility index, carr’s index   
and Hausner’s ratio 
c. Shear cell determination 
d. Critical orifice diameter determination 
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1.10.3. Angle of repose: 
Angle of repose has been used as an indirect method of quantifying powder 
flow ability, because of their relationship with interparticle cohesion. A static heap of 
powder will begin to slide when the angle of inclination is large enough to overcome 
frictional forces. This sliding will stop when the angle of inclination is below to that 
of the required to overcome adhesion/cohesion, i.e. sliding occurs until the 
gravitational forces balance the inter-particle forces. This balance of forces causes the 
powder poured from a container onto a horizontal surface to form conical mount or 
heap. The sides of the heap formed in this way make an angle with the horizontal 
which is called the angle of repose represented by φ  
It is given by 
θ= Tan-1(h/r) 
Where  θ = Angle of repose 
        h = height of heap 
r =horizontal surface radius of heap. 
 
Three are different methods of determining angle of repose such as 
1. Fixed height cone method 
2. Fixed base cone method 
3. Tilting table method 
4. Rotating cylinder method 
 
1.10.4. Bulk density:    
Bulk density is a property of powders, granules and other divided solids. It is 
defined as the mass of many particles of the material divided by the total volume they 
occupy. The total volume includes particle volume, inter-particle void volume and 
internal pore volume. Bulk density is not an intrinsic property of a material; it can 
change depending on how the material is handled. For example, a powder poured in to 
a cylinder will have a particular bulk density; if the cylinder is disturbed, the powder 
particles will move and usually settle closer together, resulting in a higher bulk 
density. For this reason, the bulk density of powders is usually reported both as 
"freely settled" and "tapped" density (where the tapped density refers to the bulk 
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density of the powder after a specified compaction process, usually involving 
vibration of the container.) 
 
Bulk density= fractional solid content × true density 
 
1.10.5. Melting point: 
It is defined as the temperature at which the pure liquid and solid exist in 
equilibrium. If the melting point is more, solubility of drug decreases and vice versa. 
 
Porosity:  
The porosity of voids of the powder is defined as the ratio of the void volume 
to bulk volume of the packing. 
 
Porosity is frequency expressed in present, Ex 100 the release of solid drug 
from a tablet involves the simultaneous penetration of the surrounding liquid, 
dissolution of drug and leaching out of the drug through interstitial channels or pores. 
For penetration of surrounding liquid in large amount, numerous pores must be 
present which enables faster release of drug. Thus, an increase in porosity increases 
the dissolution rate of the drug. 
 
1.11. CONVENTIONAL TABLETS:    
A novel, fast-dissolving delivery system that releases active ingredients in 
seconds is one of the fastest-growing segments of the supplements marketplace.  
Advances in technology continue to break the barriers of conventional encapsulation 
methods. Today, active ingredients can be delivered with a level of convenience, 
performance and bioavailability never before seen in the marketplace. And, as our 
scientific understanding of the prevention and management of diseases continues to 
grow, companies find themselves in ever-greater competition—investing millions of 
dollars to develop novel ways of delivering nutrients orally to patients. Fast-
dissolving tablets or rapid-melt tablets are one such innovation. 
 
This novel type of delivery system offers convenience for treatment-resistant 
populations who have difficulty in swallowing oral dosage forms. The demand for 
these formulations has gone up significantly for children and older populations. They 
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are particularly convenient for pediatric and geriatric segments of the population 
because they rapidly disintegrate in the mouth without the need for chewing or 
drinking water. Fast-melting formulations even offer advantages for drug-compliant 
patients who take other orally administered pills, such as chewable, suspensions and 
effervescent tablets. When placed in the mouth, these tablets disintegrate in a few 
seconds, resulting in quick absorption of the actives through the buccal and 
oesophageal mucous, thus offering faster bioavailability of active ingredients with 
minimal side effects. Fast-melting tablets can also serve as carriers for a wide range of 
nutritional and dietary supplements including calcium, caffeine, antioxidants and folic 
acid. 
1.12. CLASSIFICATION OF TABLETS7: 
1.12.1. Disintegrating tablets: 
The most common type of tablet is intended to be swallowed and to release the 
drug in a relatively short time by disintegration and dissolution i.e, the goal of the 
formulation is fast and complete drug release In-vivo, such tablets are called 
conventional or plain tablets. A disintegrant tablets includes the following type of 
excipients: filler (if the dose of the drug is low), disintegrant, binder, glidant, lubricant 
and anti adherent. The type of lubricant and filler can also be of significant 
importance for tablet disintegration. Tablet disintegration may also be affected by the 
production conditions during manufacture. Important samples are the design of 
granulation procedures(will affect  the physical properties of the granules), mixing 
conditions during the addition of  lubricants and antiadherents and the applied punch 
force during tabletting and the punch force during tabletting and the punch force- 
relationship. 
 
1.12.2. Effervescent tablets 
Effervescent tablets are dropped into a glass of water before administration, 
during which carbon dioxide is liberated. This facilitates tablet disintegration and drug 
dissolution; the dissolution of the tablet should be completed within minutes as 
mentioned above the Effervescent carbon dioxide is created by a reaction in water 
between a carbonate and bicarbonate and a weak acid such as citric or tartaric. 
Effervescent tablets are used to obtain rapid drug action, for example analgesic drugs, 
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or to facilitate the intake of drug, for example for vitamins. The amount of sodium 
bicarbonate in an effervescent tablet is quite often high (about 1gm). After dissolution 
of such a tablet, a buffered water solution will be obtained which normally 
temporarily increase the pH of the stomach. The result is rapid emptying of the 
stomach and the residence time of the drug in the stomach will thus be short, which 
increases the absorption of the drug in the intestine.  
 
1.12.3. Dispensing tablets 
Dispensing tablets are intended to be added to a given volume of water by the 
pharmacist or the consumer, to produce a solution of a given drug concentration. 
Materials that have been commonly incorporated in dispensing tablets include  mild 
silver proteinate, bichloride of mercury, merbromin, and quarternary ammonium 
compounds. The dispensing tablet comprises of the excipients which are soluble in 
water. The main difficulty with this formulation is the above mentioned excipients are 
highly toxic and extremely hazardous. 
 
1.12.4. Hypodermic tablets 
Hypodermic tablets comprises of one or more drugs with other readily water 
soluble ingredients and are intended to be added to sterile water or water for injection. 
Hypodermic tablets are less used today in this country because their use increases the 
likely hood of administering a non sterile solution. 
 
1.12.5. Tablet triturates 
Tablet triturates are small, usually cylindrical, molded, or compressed tablets. 
The drugs employed in such products were usually quite potent and were mixed with 
lactose and possibly a binder such as powdered acacia, after which the mixture was 
moistened to produce a moldable, compactable mass. This mass was forced into the 
holes of a mould board fabricated from wood or plastic, after which the tablets are 
ejected using a peg board, whose pegs matched the holes in the mould. The tablets 
were allowed to dry and ready for dispensing.   
   
1.12.6. Lozenges  
Lozenges are the tablets that dissolve slowly in the mouth and so release the 
drug dissolved in the saliva. Lozenges are used for local medication in the mouth or 
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throat, e.g. with local anesthesia, antiseptic and antibiotic drugs. They can thus be 
described as slow release tablets for local drug treatment. In addition, lozenges are 
often colored and include a flavor. The choice of filler and binder is of particular 
importance in the formulation of lozenges, as these excipients should contribute to a 
pleasant taste or feeling during tablet dissolution .Examples of fillers are glucose, 
sorbital and mannitol. Most common binder is gelatin. Lozenges are prepared by 
compaction at high pressures in order to obtain tablet of high mechanical strength and 
low porosity which can dissolve slowly in the mouth over a period of perhaps 30 
minutes or less. 
 
1.12.7. Sublingual and buccal tablets 
Sublingual and buccal tablets are used for drug release in the mouth followed 
by systemic uptake of the drug. A rapid systemic drug effect can thus be obtained 
without first pass liver metabolism. Sublingual tablets are placed below the tongue 
and buccal tablets are placed in side of the cheek. Sublingual tablets and buccal 
tablets are often small and porous, latter facilitating fast disintegration and drug 
release. Buccal and sublingual tablets should be formulated with bland excipients, 
which do not stimulate salivation. These tablets should be designed such that they do 
not disintegrate but rather dissolve slowly, typically over a period of 15 to 30 minutes. 
 
1.12.8. Chewable tablets 
Chewable tablets are chewed and thus mechanically disintegrated in the 
mouth. The drug is, however, normally dissolved in the mouth but swallowed and 
dissolves in the stomach or intestine. Thus, chewable tablets are used primarily to 
accomplish a quick and complete disintegration of the tablet and hence obtain a rapid 
drug effect or to facilitate the intake of the tablet. A common example of the former is 
antacids tablets. In the latter case, the elderly and children in particular have difficulty 
in swallowing tablets, and so chewable tablets are attractive forms of medication. 
Important examples are vitamin tablets. Flavouring and coloring agents are common. 
Sorbital and mannitol are the common examples for fillers. 
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1.12.9. Dental cones 
Dental cones are relatively minor tablet forms that are designed to be placed in 
the empty socket remaining following a tooth extraction. Their usual purpose is to 
prevent the growth and multiplication of bacteria in the socket such extraction by 
employing a slow releasing antibacterial compound, or to reduce bleeding by 
containing an astringent or coagulant. The usual vehicles of these tablets are sodium 
bicarbonate, sodium chloride, or an amino acid. 
 
1.12.10. Implantation tablets 
Implantation tablets or depot tablets are designed for subcutaneous 
implantation in animals or man. Their purpose is to provide prolonged drug effects, 
ranging from one month to one year. The tablets are usually small, cylindrical or 
rosette shaped forms, and are typically not more than 8mm in length. The safety 
problems include surgical technique to discontinue therapy, and tissue toxicity in the 
area of implantation site. These forms are mostly replaced by the diffusion controlled 
silicone tubes filled with drug or bio degradable polymers that contain entrapped drug 
in a variety of forms. 
 
1.12.11. Vaginal tablets 
Vaginal tablets or inserts are designed to undergo slow dissolution and drug 
release in the vaginal cavity. The tablets are pear shaped or ovoid to facilitate 
retention in vagina. This tablet form is used to release anti bacterial agents , 
antiseptics or astringents to treat vaginal infections, or possibly to release steroids for 
systemic absorption. The tablets are often buffered to promote a pH favorable to the 
action of a given antiseptic agent. The tablets should be designed to be compatible 
with some type of plastic tube inserter, which is usually employed to place the tablet 
in the upper region of vaginal tract. 
 
1.12.12. Enteric coated tablets 
All enteric coated tablets are a type of delayed release tablets. In human drug 
application, a product may be designed to pass through the stomach intact and then 
release gradually for several hours or longer in intestines. The compendial 
specifications for an enteric coated tablet are that all of the six tablets placed in 
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separate tubes of USP disintegration apparatus remain intact after 30 minutes of 
exposure in simulated gastric fluid at 37 ± 20C and then disintegrate within the time 
specified for the products monograph, plus 30 min. if one or two tablets fail to 
disintegrate completely in the intestinal fluid. The test is repeated on 12 additional 
tablets; not less than 16 of the total 18 tablets tested must disintegrate completely. 
 
1.12.13. Sugar or chocolate coated 
Sugar coated tablet role was to produce an elegant, glossy, easy to swallow 
tablet dosage form. The process developed was time consuming. Earlier sugar coating 
doubled the tablet weight. Today water soluble polymers are incorporated in the sugar 
solution, automated spray coating equipment is employed, and high drying efficiency 
side vented coating pans are used and the process can be completed in a day or less. 
    
1.12.14. Film coated tablets: 
Film coated tablets were developed as an alternative procedure to the 
preparation of coated tablets in which the drug was not required in the coating. The 
initial film coating compositions employed one or more polymers, which usually 
included a plasticizer for the polymer and possibly a surfactant to facilitate spreading. 
The film coating process was an attractive tablet coating method since it permitted the 
coating of the tablet in a period of one or two hours. Polymers such as hydroxypropyl 
cellulose and hydroxypropyl methylcellulose, which are dissolved in water with an 
appropriate plasticizer, are now widely used to prepare immediate release film coating 
tablets. 
 
1.13. INACTIVE INGREDIENTS7:  
The selection and testing of non active ingredients or excipients in tablet 
formulas present to the formulator the challenge of predictive foresight. 
 
Two major classifications of additives by function include those which affect 
the compressional characteristics of the tablet, 
 
¾ Diluents 
¾ Binders and adhesives 
¾ Lubricants, anti adherents, and glidants. 
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And those which affect the biopharmaceutics, chemical and physical stability 
and marketing considerations of the tablet, 
¾ Disintegrants 
¾ Colors 
¾ Flavors and sweeteners 
¾ Miscellaneous components ( e.g., buffers and adsorbents) 
 
1.13.1. Diluents:  
Although diluents are normally thought of as inert ingredients, they can 
significantly affect the biopharmaceutics, chemical and physical properties of the final 
formulation. The classic example of calcium salts interfering with the absorption of 
tetracycline from the gastrointestinal tract was presented by Bolger and Gavin. The 
interaction of amine bases or salts with lactose in the presence of alkaline lubricants, 
and subsequent discoloration, emphasized that excipient inertness may often not exist 
in the design of drug dosage forms. 
 
Usually tablets are designed so that the smallest tablet size which can be 
conveniently compressed is formed. Thus, where small dosage level drugs are 
involved, a high level of diluent or filler is necessary. If however, the dosage level is 
large, little or no diluent will be required, and the addition of other excipients may 
need to be kept to be kept to a minimum to avoid producing a tablet that is larger than 
acceptable. In such large drug dosage situations, nevertheless, excipient materials 
must often be added to produce a granulation or direct-compression mixture which 
may be compressed into acceptable tablets. 
 
Eg: Sucrose, Mannitol, Sorbitol, Microcrystalline cellulose, Dextrose, 
Amylose etc8.  
 
1.13.2. Binders and adhesives: 
Binders or adhesives are added to tablet formulation to add cohesiveness to 
powders, thereby providing the necessary bonding to form granules, which under 
compaction form a cohesive mass or compact referred to as a tablet. The primary 
criterion when choosing a binder is its compatibility with the other tablet components. 
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Secondarily, it must impart sufficient cohesion to the powders to allow for normal 
processing (sizing, lubrication, compression, and packaging), yet allow the tablet to 
disintegrate and the drug to dissolve upon injection, releasing the active ingredients 
for absorption.   
 
Eg: Acacia, Tragacanth, Sucrose, Gelatin, Poly vinyl pyrolidine, 
Polymethacrylate etc,. 
 
1.13.3. Disintegrants:  
The purpose of the disintegrants is to facilitate the breakup of the tablet by 
swelling after administration. Disintegrating agents may be added prior to granulation 
or during lubrication step prior to compression or at both processing steps. Six basic 
categories of disintegrants have been described: starches, clays, cellulose, algins, and 
gums and miscellaneous. Intra granular and extra granular disintegrating agents were 
reviewed by shot- ton and leonard. The extra granulation formulations disintegrated 
more rapidly than the intra granular ones, but the later resulted in a much finer 
dispersion of particles.  
 
Eg: Sodium starch glycolate, Celluloses, Alginates, Resins etc,. 
 
1.13.5. Lubricants, Antiadherants, and Glidants: 
The primary function of the tablet lubricants is to reduce the friction arising at 
the interface of the tablet and the die wall during compression and ejection. 
                 
• Lubricants     : Reduce friction between the granulation and die wall during    
compression and Ejection. 
  Eg: Boric acid, Sodium chloride, Stearic acid etc,. 
• Antiadherents: Prevent sticking to the punch and, to a lesser extent, the die 
wall. 
  Eg: Talc, Magnesium stearate, Colloidal silica etc,. 
• Glidants : Improve the flow characteristics of the granules. 
  Eg: Corn starch, Aerosil etc,. 
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1.13.6. Colors, Flavors and Sweeteners: 
The use of the colors and dyes in tablet making has served three purposes; 
disguising of off color drugs, product identification and production of a more elegant 
product. With the continual decertification of many synthetic dyes, pharmaceutical 
manufacturers are becoming quite concerned as to how future tablet formulations will 
be colored. Two forms of colors have typically been used in tablet preparation. These 
are the FD&C and D&C dyes – which are applied solutions, typically in the 
granulating agent- and the salt forms of these dyes. Lakes and dyes that have been 
absorbed on a hydrous oxide and usually are employed as dry powders for coloring. 
When using water soluble dyes, pastel shades usually show the least mottling from 
uneven distribution in the final tablet. When wet granulation is employed, care should 
be taken to prevent color migration during drying. 
 
Flavors are usually limited to chewable tablets or other tablets intended to 
dissolve in the mouth. Flavor oils that are added to the tablet during granulation in 
solvents, or dispersed on clays and other absorbents or emulsified in aqueous 
granulating agents. Usually, the maximum amount of oil that can be added to the 
granulation without influencing its tablet characteristics is 0.5 to 0.75%. 
 
The use of sweeteners is primarily limited to chewable tablets to exclude or 
limit the use of sugars in tablets. Mannitol is 72% as sweet as sucrose. Until recently, 
saccharin was the only artificial sweetener available. This material is about 500 times 
sweeter than sucrose. Its major disadvantage is it has bitter after taste and has been 
reported to be carcinogenic. Aspartame is the sweetener which replaced saccharin 
very much in the formulation now a days. But the primary disadvantage with 
aspartame is its unstable nature in the presence of moisture. 
 
1.14 PROCESSING PROBLEMS9:  
In the normal process of developing formulations, and in the routine 
manufacture of tablets, various problems occur. Sometimes the source of the problem 
is formulation, the compression equipment, or a combination of two.  
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TABLE – 1 
PROCESSING PROBLEMS OF TABLETS 
PROBLEMS CAUSES REMEDY 
CAPPING AND 
LAMINATION 
• Granulation too dry 
• Compression too hard 
• Damaged upper punches 
• Machine RPM too fast 
• Excessive lubrication 
• Less binder in granules 
• Entrapped air in       
   granules 
 
• Increase moisture content 
• Reduce compression  
• pressure 
• Replace the tools which are damaged 
• Reduce machine speed 
• Reduce or change the  
• lubricant 
• Increase binder concentration 
• Improve granulation by using tapered 
dies 
CHIPPING 
• Damaged punches or     
   dies 
• Compression too fast 
• Faulty machine testing 
• Less binder 
• Compression too soft 
• Replace the damaged punches or 
dyes 
• Reduce compression speed 
• Reduce the speed 
• Increase binder 
• Increase the compression pressure 
STICKING, 
PICKING, 
      FILMING 
• Compression too soft 
 
• Uneven granulation 
• High moisture content 
 
• High relative humidity 
• Improper lubrication 
• Damage of upper punch 
• Increase compression pressure 
• Improve granulation 
• Reduce moisture content in 
granulation 
• Use dehumidifier 
• Improve lubrication 
• Polish the punches 
• Buffering the punches with 
lubricants 
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NON 
UNIFORM 
WEIGHT 
• Machine RPM too fast 
• Non uniform granules 
• Restricted free flow of  
   granules 
• Granules sticking to  
    lower punches 
• Feed frame/ hopper flow  
    Restricted 
• Reduce machine speed 
• Provide uniform  
   granules 
• Add glidant to improve  
    the flow properties 
• Improve lubricant 
• Adjust the hopper to get  
    free flow 
BINDING 
• Rough edges 
• Vertical score marks on  
    the edges 
• Increase lubricants 
• Decrease the size of the  
   granules and use tapped  
            dyes. 
DISSOLUTION 
• Large Granules 
• Tablets Too Hard 
• Excess lubricants 
• Reduce granules size 
• Reduce tablet hardness 
• Reduce compression  
    hard ness 
COLLAR 
FORMATION 
• Too Much Fines • Reduce fines 
BLACK 
MARKS 
ON 
TABLETS 
• Improper feed frame  
   setting 
• Excessive moisture 
• Over sized granules 
• Granules having black  
    particles prior to   
             compression 
• Lubricants, grease or oil  
   may be contaminating    
              the powder 
• Improve feed frame  
   setting 
• Avoid excesive  
    moisture 
• Reduce granules size 
• Avoid contamination  
   with oil or grease 
DELAYED 
DISINTEGRAT
ION 
• Compression Too Hard 
• Over granulation 
 
• Excess blending times  
          with lubricants or glidants 
• Reduce the compression  
    pressure 
• Improve the granulation 
• Reduce the blending  
    time of lubricants 
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1.15 TABLET COATING10:   
Tablet coating is the application of coating composition to moving bed of 
tablets & concurrent use of heated air to facilitate evaporation of solvent. 
 
1.15.1 FILM COATING: 
Film coating is deposition of thin film of polymer surrounding the tablet core. 
Conventional pan equipments may be used but now-a-days more sophisticated 
equipments are employed to have a high degree of automation and quality coating. 
The polymer is solubilised or suspended in solvent & other additives like plasticizers 
and pigments are added. Resulting solution is sprayed onto a rotated tablet bed. The 
drying conditions cause removal of the solvent, giving thin deposition of coating 
material around each tablet11. 
 
Factors to be considered during coating process: 
• Check and ensure that the coating pan and other equipments are cleaned as per 
specification. 
• Check and ensure that the speed of the coating pan, gun to bed distance, inlet 
and exhaust air temperature, spray rate, spray type, number of guns, 
temperature of the coating solution is as per specification. 
• After coating is completed, samples are collected for dissolution testing and 
weight variation. 
 
Coating parameters to be considered: 
• Spray gun model 
• Pan load (kg) 
• Pan speed (rpm) 
• Spray procedure 
• Spray rate (g/min or ml/min) 
• No. of spray guns 
• Distance between spray guns (cm) 
• Distance between spray gun & tablet bed 
• Main inlet pressure (kg/cm²) 
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• Atomization pressure (kg/cm²) 
• Inlet air temperature (ºC) 
• Tablet bed temperature (ºC) 
• Position of dampers – inlet, Outlet 
• Quantity of coating suspension in the liquid vessel (kg/lit) 
• Average weight of preheated core tablets (mg) 
 
1.15.2 PROCESS VARIABLES DURING FILM COATING: 
The variables to be controlled during pan spray film coating processes are: 
1. Pan variables: 
¾ Pan design/baffling 
¾ Speed 
¾ Pan load 
 
2. Process- Air 
¾ Air quality 
¾ Temperature 
¾ Airflow rate/volume/balance 
 
3. Spray variables 
¾ Spray rate 
¾ Degree of atomization 
¾ Spray pattern 
¾ Nozzle to bed distance  
 
1.15.4 COATING PROBLEMS12: 
Picking and sticking: 
This is when the coating removes a piece of the tablet from the core. It is 
caused by over-wetting the tablets, by under-drying or by poor tablet quality 
 
Bridging:  
This occurs when the coating fills in the lettering or logo on the tablet and is 
typically caused by improper application of the solution, poor design of the tablet 
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embossing, high coating viscosity, high percentage of solids in the solution or 
improper atomization pressure. 
Capping:  
This is when the tablet separates in laminar fashion. The problem stems from 
improper tablet compression, but it may not reveal itself until the coating is started.  
 
Erosion:  
This can be the result of soft tablets, an over-wetted tablet surface, inadequate 
drying, or lack of tablet surface strength. 
 
Twinning:  
This is the term for two tablets that stick together, and it’s a common problem 
with capsule shaped tablets. Assuming you don’t wish to change the tablet shape, you 
can solve this problem by balancing the pan speed and spray rate. Try reducing the 
spray rate or increasing the pan speed. In some cases, it is necessary to modify the 
design of the tooling by very slightly changing the radius. The change is almost 
impossible to see, but it prevents the twinning problem. 
 
Peeling and frosting: 
This is a defect where the coating peels away from the tablet surface in a 
sheet. Peeling indicates that the coating solution did not lock into the tablet surface. 
This could be due to a defect in the coating solution, over-wetting, or high moisture 
content in the tablet core. 
 
Chipping: 
This is the result of high pan speed, a friable tablet core, or a coating solution 
that lacks a good plasticizer. 
 
Mottled color: 
This can happen when the coating solution is improperly prepared, the actual 
spray rate differs from the target rate, the tablet cores are cold, or the drying rate is out 
of specification. 
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Orange peel: 
This refers to a coating texture that resembles the surface of an orange. It is 
usually the result of high atomization pressure in combination with spray rates that are 
too high. 
 
1.2.5 COATED TABLET EVALUATION13: 
A number of test methods are employed: 
1) Adhesion tests with tensile strength testers have been used to measure the 
force required to peel the film from the tablet surface. 
2) Diametric crushing strength of coated tablets can be determined with a 
tablet hardness tester. 
3)  Coated tablet disintegration and / or dissolution must also be assessed.  
The coating should have a minimal effect on tablet disintegration or 
dissolution. 
4) Stability studies must be conducted on coated tablets to determine whether 
the temperature and humidity changes will cause film defects. 
5) Attempts have been made to quantify film surface roughness, hardness and 
colour uniformity through instrumental means, but in general visual 
inspection is sufficient to define relative coated tablet quality14. 
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2. LITERATURE REVIEW 
 
¾ B.Jayakar15 et al., (2010) Prepared rapid release gelcaps of Diphenhydramine 
HCl,      for treatment of allergic symptoms and irritant cough. By Direct 
compression method using Pregelatinised maize starch and croscarmellose 
sodium in various concentrations. The granules showed satisfactory flow
properties and compressibility Diphenhydramine HCl successful formulation
was found. 
 
¾ Biljana Govedarica16 et al., (2011),  Formulation and evaluation of immediate 
release tablets with different types of Paracetamol powders prepared by direct
compression.The mechanical strength of tablets several kind of “ paracetamol for
direct compression “ as present in the combination with both investigated super
disntegrate such as vivasol and polyplasdone x-10 showed faster dissolution time 
and dissolution rate in compression. 
 
¾ Nielsen and Bjerring17 et al., (1991), summarized that the analgesic efficacy of 
single doses of immediate release Paracetamol 500 mg and 1000 mg, sustained
release paracetamol 2000 mg, and placebo was evaluated over a 12 hrs period in
10 healthy volunteers. The efficacy was related to the concurrent plasma
concentrations of paracetamol. Experimental pain was induced by brief
cutaneous application of argon laser pulses, and the analgesic effect was assessed 
as change in pricking pain threshold.  
 
¾ Wayne M. Camarco18 et al., (2009), studied the incorporation of low dose co-
active into acetaminophen (APAP) based solid dosage formulations is normally
achieved by wet-granulation techniques. Direct compression methods could offer 
a simplified and more economical alternative, as long as content uniformity 
criteria can be fulfilled. 
 
¾ Surendra C. Mehta19 et al., (1994), an evaluated acrylic polymer-wax matrix 
system for oral sustained-release tablets of diphenhydramine HCl incorporating 
Eudragit L in a carnauba wax matrix. In this polymer-wax system, carnauba wax 
maintained the integrity of the matrix, whereas Eudragit L slowly eroded in the
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matrix as the drug was released. Thus, the area-to-volume ratio of the tablet 
remained constant over the duration of the drug release. In vitro drug release
studies were conducted at physiological pH that exist in the gastrointestinal tract. 
Drug release rates decreased as the polymer: drug ratio increased from 1:2 to 2:1. 
The drug release rate was faster in pH 7.5 phosphate buffer than in 0.1 N HCl
solution.  
 
¾ Takeshi Kawaguchi20 et al., (2002), evaluated the use of a rotating fluidized-
bed granulator to produce acetaminophen granules with sufficient binding force 
between particles and good plasticity. Ascorbic acid was used to compare the
relationship between the granules and sample wetness. 
 
¾ Aniruddha21  et al., (2011) indicated that moist granulation technique (MGT) 
appears to be applicable in developing controlled release formulation of
Acetaminophen tablets. A small amount of granulating fluid was added to
powder bland to activate a dry binder at 2% and facilitate agglomeration then 
moisture absorbing material was added to absorb any excesses moisture by 
adding MCC in this  way a drying step is not nessecery. 
 
¾ Joshua E. Lane22 et al., (2002)proved that both acute and chronic overdoses of 
Acetaminophen can be fatal. Patient ingested approximately 5.0 to 6.5 g of
acetaminophen daily for 6 to 8 weeks via multiple medications. The inclusion of
acetaminophen in numerous medications combined with the frequency of use of
acetaminophen necessitates an increased concern for not only acute but also 
chronic acetaminophen toxicity. 
 
¾ Marieke Nauta23 et al., (2009), proved that the oral acetaminophen/ codeine 
can be used for postpartum pain. Codeine has opioid-related adverse effects and 
may not be safe during breastfeeding in the postpartum period for all neonates.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are devoid of opioid-related 
adverse effects and could be a possible alternative for analgesia in postpartum 
pain. They compared the analgesic effect and safety profile of
Acetaminophen/ codeine with NSAIDs in the management of pain after 
laparotomy.  
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 27 
 
 
¾ Elke Leinisch24 et al., (2005) The efficacy of intravenous acetaminophen
(1000 mg) in the treatment of acute migraine attacks as an alternative to
parenteral application of lysine acetylsalicylate or triptans was investigated, 
using a multi-center, randomized, double-blind, placebo controlled study design. 
 
¾ Terrence25 et al., (2007) proved that the acetaminophen  or diphenhydramine 
premedication before more than 50% of blood component transfusions prevents
the Febrile nonhemolytic and allergic reactions which are the most common
transfusion reactions. 
 
¾ MA Naeem 26et al., developed and characterized bilayer tablet formulations of 
tramadol HCl (TmH) and acetaminophen (AAP) microparticles. Coacervation
via temperature change was the encapsulated method used for the preparation of
the microparticles, with ethyl cellulose (EC) of medium viscosity as the polymer 
for extending drug release. The microparticles of the two drugs were prepared
separately and then compressed into bilayer tablets. 
 
¾ Nourudin W.Ali27.et al., (2011) stability indicating methods for simultaneous 
determination of paracetamol and diphenhyramine HCl in their binary mixture 
and in presence of P-aminophenol, and also determine potential impurity and
degradation product of Paracetamol were developed. Analysis of Paracetamol
and Diphenhydramine in their paranaceutical formulation without interference of 
other dosage forms additive and the result were statistically compared and
official method.  
 
¾ P.V.Swamy28 et al., (2009), designed Orodispersible tablets of pheniramine 
maleate by effervescent method. The tablet containing mixture of sodium
bicarbonate, tartaric acid with super disintegrants. Evaluation of the formulation 
showed an invitro dispersion time of approximately 40seconds, which facilitates
the fast dispersion in mouth. 
 
¾ D.M.Patel29 et al., (2004), studied that formulations of  orodispersible tablets of 
Rofecoxib using sodium starch glycolate, crospovidone and croscarmellose
sodium along with mannitol as diluent and the tablets were evaluated.  
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¾ S. A. Sreenivas30 et al., (2005), studied on an orodispersible tablets new fangled 
drug delivery system to solve the problem of Dysphagia and to improve patient
compliance. Orodispersible tablets have emerged as an alternative to
conventional and dosage forms. These tablets are very useful in the condition
where water is not available and in case of motions sickness (kinetosis), sudden 
episodes of coughing during common cold, allergic conditions and bronchitis. 
 
¾ Nagendrakumar31 et al., (2009), prepared and evaluate fast dissolving tablet of 
Fexofenadine Hcl  by Effervescent method using crospovidone, croscarmellose 
sodium and sodium starch glycollate as super disintegrants. The formulation
showed the in vitro dispersion time of 290 seconds when compared to
commercial tablet. 
 
¾ Sarasija Suresh32 et al., (2008), designed and evaluate Fast dissolving tablet of 
Clonazepam by direct compression method using super disintegrants viz.
croscaramellose sodium, sodium starch glycollate along with Mannitol to
enhance mouth feel. Time taken for the in vitro dispersion time of the
formulation was found to be approximately 13seconds. 
 
¾ T.V.Rao33 et al., (2008),worked on the formulation and evaluation of cefadroxil
dispersible tablets by direct compression technique using superdisintegrants such
as crospovidone, croscarmellose sodium, sodium starch glycolate. The tablets 
were evaluated for hardness, weight variation, friability, and wetting time, D.T
and in vitro dissolution studies. It was concluded the dispersible tablets of
cefadroxil with cros- carmellose sodium showing rapid release rate/enhance
dissolution hence better patient compliance and effective therapy. 
 
¾ Mallikarjuna shetty34 et al., (2008), studied the fast dispersible Aceclofenac 
tablets and effects of functionality of superdisintegrants. Aceclofenac fast
dispersible tablets have been prepared by direct compression method. Effect of 
superdisintegrants such as croscarmellose sodium, sodium starch glycolate and
crospovidone on wetting time, disintegration time, drug content, in-vitro release 
and stability parameters has been studied. It is concluded that the dissolution 
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parameters and disintegration times increased with increase in the level of
croscarmellose sodium and sodium starch glycolate in tablets and were sensitive
to high humidity conditions. 
 
 
¾ T.V.Rao35 et al., (2008) developed a fast dissolving of Simvastatin by direct 
compression with moisture activation technique i.e., exposed in humidity
chamber 75% RH at 30°c for 1hr, which offers a new range of product having
desired characteristics and intended benefits. Fast dissolving tablets of
Simvastatin were prepared by using effervescent mixture i.e., sodium
bicarbonate and citric acid, mannitol, spray dried lactose. All the formulations
were evaluated for hardness, friability, weight variation, absorption ratio, in vitro
dispersion time and in vitro drug release studies. All effective pleasant tasting 
and stable formulation F4 containing sodium bicarbonate and citric acid was 
found to have hardness 3.8kg/cm2 in vitro dispersion time was 10 second, 
maximum amount of drug released with in 5 min than other prepared and 
marketed formulati . 
 
¾ Shishu36 et al., (2007), prepared taste masked granules of rapidly disintegrating
tablets of Chlorpheniramine maleate. The taste masked granules were prepared
to using eudragit (E-100) by the extrusion method, sodium starch glycolate as a 
superdisintegrant. The prepared tablets containing the taste masked granules
having sufficient strength of 3.5Kg/cm2 were evaluated for taste by both 
spectrophotometric methods and through panel testing. Panel testing data
collected from 20 healthy volunteers indicate successful formulation of oral fast 
disintegrating tablets. 
 
¾ Sheetal Make37 et al., (2007), designed formulation and evaluation of 
oxcarbazepine FDT. FDT of oxacarbazepine were prepared containing Avicel
pH102 as a diluent and Ac-Di-Sol as a superdisintegrant by wet granulation 
process. All the formulation were evaluated for characteristics such as hardness,
friability, weight variation, wetting ability, disintegration time and dissolution
rate and found drug release of not less than 90% within 30min. Since the drug is 
poorly water soluble drug release was tested in various media and the effect of
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surfactant on drug release was studied. 
  
¾ Aithal.k.38 et al., (2006), developed once daily fast dissolving tablets of 
Granisetron Hcl by direct compression method using superdisintegrants.
Formulations containing crospovidone and croscarmellose sodium shows
shortest disintegration time. 
¾ Sajal Kumar Jha39 et al.,  (2008), developed and evaluates the melt in mouth 
tablets of Halopridol by direct compression method using superdisintegrants as
croscarmellose sodium, sodium starch glycolate and crospovidone. formulation
containing higher concentration of crospovidone decrease the disintegration time
and optimize the drug release. 
 
¾ G. Abdelbary40 et al., (2004), evaluated the disintegration profile of RDT and 
correlation with oral disintegration. RDT was manufactured by main
commercialized technologies. The excellent disintegration time and correlation
was found.Qualitative mouth feel was achieved by comparing the thickness of 
the tablet.  
 
¾ Mohanad Naji Sahib41 et al., (2009), designed Prednisolone tablets as a 
potential colon delivery system by using wet granulation & coating. The tablet
contains the Acetone, Dibutyl phthalate, Ethanol 99%, Eudragit L 100, S100, 
Glucose, Mannitol, Starch, Lactose, Hydrochloric acid, Ethyl cellulose,
Methanol, Microcrystalline cellulose-Avicel -PH 101, PH 102, PH 302, 
Polyvinylpyrrolidone (PVP K 30), Potassium dihydrogen phosphate, Sodium
hydroxide, Zinc stearate, and Prednisolone. Eudragit S 100 coating is not 
allowing the drug to release in pH less than 7. 
 
¾ Rabia Bushra42 et al., (2010), formulated enteric coated ibuprofen tablets in 
order to avoid gastric mucosal irritation, diffusion of drug across mucosal lining 
and to let active ingredient be absorbed easily in small intestine. The formulation
was developed and manufactured through the direct compression process, the
simplest, easiest and most economical method of manufacturing. Enteric coating
was done using an Opadry white subcoating and an aqueous coating dispersion
of Acryl-Eze. 
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¾ K. L. Senthil Kumar43 et al., (2010), developed enteric coated tablets of 
Didanosine to get resistance from Gastric juice when it presents in stomach,
because Didanosine is incompatible with gastric juice. The tablets were prepared 
by using wet granulation technique using polymer Ethyl Cellulose std 100 FP,
Ethyl Cellulose Med 70 P, Ethyl Cellulose Med 50 P and other excipients are
Povidone Micro crystalline Cellulose in different ratios. These polymers and 
excipients are used for sustained the drug release. And 20% solution of Eudragit
L 100 with isopropyl alcohol used for enteric coat. And diethyl phthalate added
as polishing agent in enteric coat solution. 
 
¾ Vaishali44et al., (2010) prepared immediate-release enteric-coated pellets of 
aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a 
gastrointestinal intolerance as its serious side effect. Formulation of enteric-
coated pellets with improved solubility of aceclofenac could address both of 
these problems. The goals, pellets were prepared by extrusion–spheronization 
method using pelletizing agents that can contribute to the faster disintegration
and thereby improve the solubility of the drug. Different disintegrants like β-
cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in 
order to further improve disintegration time.  
 
¾ Bhaunia biswajit45 et al., (2006) described orodispersible tablet or uncoated 
tablets intended to be placed in the mouth where they disperse before being 
swallowed. Orodispersable tablets disintegrate with in 3 min tablets and
capsules. Orodispersible tablets in which cross povidone, crosscormellose 
sodium these are the super disintegrates are used  rapidly release of the 
Amlodepine  by using and  maintain the release profile. Syed azeem hyder46 et
al., (2011).  Prepared and evaluated the immediate release tablets of Rupatadine 
Fumarate by using different disintegrating agents by using manitol, MCC, cross-
povidone , alginic acid as super disintegrates in different concentrations. All 
formulations evaluated for precompression and post compression. The result 
showd the cross-povidone shows the short disintegration time. 
 
¾ Rai V.K47.et al., (2009), carried out an optimization of immediate release tablet 
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of Raloxifene hydrochloride by wet granulation method. Different filters, 
binders, disintegrants and lubricant were taken as variables. 
 
¾ Vasanth kumar Sekar48 et al., (2008)  prepared immediate release tablet of 
Telmisartan anti hypertensive drug   by using cross povidone at intra granular,
extra granular and partial intra and extra granular level of addition and increases
the rate of release of drug from dosage form.  
 
 
¾ Pani Nihar Ranjan49et al., (2011),   carried out an optimization and formulation 
of immediate release tablet of Nateglinide by using 32 factorial design and 
compatability of nateglinide with selected excipients in the developent of 
immediate release tablet of Nateglinide by thermal and also thermal stress testing 
techniques. 
 
¾ Rizvanulla50 et al., (2011), prepared and evaluated the Oxcarbazepine fast 
dissolving tablets by using various super disintegrates. Batch is prepared without 
disintegrants designated as four differentgroups of formulation chemical
incompatability studies confirm that there is no interaction between drug and 
excipients used in the formulation by direct compression method. 
 
¾ Honey goel51 et al., (2008) described orally disintegrating system have amongst 
the orally drug delivery systems due to highest component of compliance the
gastric and pediatrics. Drug satisfactory absorption from the oral mucosa 
immediate pharmacological action can be formulated. A variety of dosage forms
like tablets, films, wafers, chewing gums, micro particles, nano-particles. 
 
¾ Jensc.Nielsen52 et al., (1991) studied the hypoalgesic effect of paracetamol in 
flow release  and pain tablets on laser- induced pain a double-blind three way, 
cross over study  received plain paracetamol  slow tablets 100mg ever 6 hrs. 
Paracetamol 2000 mg every 12th hr and placebo. Hypoalgesia, measured by 
experimentally laser-induced pain. Slow release formulation was given once at
the start of the session. 
 
¾ Karl G. Wagner53 et al., Developed disintegrating multiple-unit tablets on a 
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highspeed rotary tablet press .Enteric coated bisacodyl pellets were compressed
into divisible disintegrating tablets on a high speed rotary tablet press and
investigated for pellet damages. 
 
¾ Shlyankevich, L. Liu54 et al., made a comparison between  USP Apparatus 2 
and 3 in Dissolution Testing of Immediate Release/Controlled Release Bilayer
Tablets. In vitro release of bilayer tablets was studied using USP apparatus 2 
(paddles) and 3 (reciprocating cylinders) in water. In case of apparatus 2 it was
noted that if the tablet landed on its CR layer it tended to adhere to the vessel and
stayed in this position for the rest of the run. 
 
¾ Chinam Niranjan Patra55 et al., developed a bilayer tablet of propranolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release 
layer and water immiscible polymers such as Ethyl cellulose, Eudragit RLPO
and Eudragit RSPO for the sustaining layer. 
 
¾ N. Damodharan56 et al., (2010), formulate and evaluated the delayed release 
Doxycycline tablets. The tablets were prepared by wet granulation method. 
Doxycycline hydrochloride, dicalcium phosphate, microcrystalline cellulose,
starch, lactose, PVP‐K‐30, sodium starch glycolate, eudragit‐L100, HPMC 
pthalate‐55, isopropyl alcohol, methylene chloride, titanium dioxide, talc,
magnesium stearate, methyl paraben, propyl paraben were used in the
formulation. Polymers like Eudragit L 100 and HPMC Phthalate are selected 
where dissolution is above pH 6 and pH 6.4 respectively. 
 
¾ Mohanad Naji Sahib57 et al., (2009), designed Prednisolone tablets as a 
potential colon delivery system by using wet granulation & coating. The tablet
contains the Acetone, Dibutyl phthalate, Ethanol 99%, Eudragit L 100, S100, 
Glucose, Mannitol, Starch, Lactose, Hydrochloric acid, Ethyl cellulose,
Methanol, Microcrystalline cellulose-Avicel -PH 101, PH 102, PH 302, 
Polyvinylpyrrolidone (PVP K 30), Potassium dihydrogen phosphate, Sodium
hydroxide, Zinc stearate, and Prednisolone. Eudragit S 100 coating is not
allowing the drug to release in pH less than 7. 
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¾ F. Siepmann58, et al., (2010), prepare and characterized polymeric film coatings 
with pH-dependent properties for oral administration; and (ii) to better 
understand the underlying mass transport mechanisms upon exposure to
simulated gastric and intestinal fluids. Propylene glycol alginate (containing free
carboxylic groups) was chosen as a pH-sensitive film former, which was blended 
with different amounts of ethylcellulose. 
 
¾ Chakraborty S. et al.,59  (2008), formulate and evaluated  pantaprazole enteric 
coated tablets. Pantaprazole 5-(difluoromethoxy)- 2-[(3,4-dimethoxypyridin-2-
yl) methylsulfinyl]- 3H-benzoimidazole is a proton pump inhibitor belongs to 
group of benzimidazole. This compound inhabits gastric acid formation and 
there it is very efficient for treatment of gastric acid duodenum  ulcers. In
aqueous media more acidic than pH 4 it suffers a practically complete 
decomposition within a period shorter than 10 minutes.  
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3.1 AIM OF THE WORK 
 
Now a day’s patients are suffering with fever and cold so that we want quick 
recovery. For this we are using two different drugs (Analgesics& anti histamines). 
Acetaminophen and Diphenhydramine combination gives very quick recovery from 
fever and cold. It is available in various type of formulations. When compared with 
these formulations the present study formulation is pharmacological responds and 
minute difficulties in formulation. The aim of the present study is to develop a
pharmaceutically stable and robust formulation of Acetaminophen 500mg and
Diphenhydramine Hydrochloride 25mg tablets comparable with innovator.  
 
This goal various types of superdisintegrant and excipient with different 
concentrations are used in various prototype trials are taken & evaluated with respect to 
various quality parameters like weight variation, friability, hardness, thickness and also 
perform various stability studies in these formulation. The formulation shall be finalized 
by comparing the in -vitro dissolution profile with that of the innovator in various pH
media by using HPLC method and produce a desirable and stable tablet.  
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3.2 PLAN OF THE WORK 
 
• Pre formulation studies. 
• Preparation of granules. 
• Evaluation of granules. 
• Formulation of different batch of coated tablets. 
• Characterization of uncoated tablets 
• Physical and chemical evaluation during and after stability studies. 
o Physical parameters like weight variation, friability and hardness. 
o Drug content uniformity 
o In-vitro drug release studies 
• Characterization of coated tablets. 
o Physical parameters like weight variation , friability and hardness 
o Drug content uniformity 
o Invitro drug release studies 
• Stability studies.  
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4. MATERIALS AND METHODS 
 
 
4.1 MATERIALS USED: 
The following were the list of excipients selected for the formulation but the
finalized list of excipients was based on the innovator product. 
 
TABLE -2 
 
S.N 
INGREDIENTS 
USED 
CATEGORY SUPPLIED BY 
1 
Acetaminophen Active Granules India, Hyderabad 
2 
Diphenhydraminehydroch
loride 
Active Wanbury pharmaceuticals, 
Hyderabad. 
3 Pre gelatinized starch Diluent SA Pharma,Hyderabad. 
4 
Micro crystalline 
cellulose 
Adsorbent Mingtai 
pharmaceuticals,Hyderabad. 
5 Povidone k-30 Binder/diluents       Roquette frères, UK 
6 Croscarmellose sodium Disintegrant            Roquette frères, UK 
7 Colloidal silicon dioxide Glident                    Evonik Degussa, SA 
8 
Stearic acid Lubricant               Tauras chemicals Ltd, 
Hyderabad, India 
9 Opadry 13B 80923 Blue Coating material   Colorcon, Hyderabad. 
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4.2 INSTRUMENTS USED 
 
TABLE - 3 
 
S.NO. 
 
NAME OF INSTRUMENT 
MANUFACTURING 
COMPANY 
1  Automatic tablet dissolution apparatus USP I Pharma Test Hyderabad 
2  Electronic thickness measurement apparatus Mitutoyos Hyderabad 
3  Friability tester USP 23 Electro Lab Hyderabad 
4  Tablet hardness tester Pharma Test, Hyderabad 
5  
Electronic LOD measurement apparatus 
(Halogen Moisture Analyzer) 
Mettler Toledo, Mumbai 
6  Tap Density Apparatus USP Electro lab, Hyderabad 
7  
Electronic weighing balance, 150 
Kg,6kg,30gms 
Mettler Toledo, Mumbai 
8  Lab stirrer 8 Liters Eltech, Hyderabad 
9  Single Deck Sifter SWECO, Hyderabad 
10  Octagonal Blender 10 Liters Saan, Hyderabad 
11  Tablet compression machine 12 station RIMEK, Pune 
12  Fluid Bed Processor (FBP) FBE – 5 P+am Glatt, Hyderabad 
13  Tablet Coating Machine (Neocota – 5 kg) Neomachines, Ahmedabad 
14  Moisture Content ( KF Titrino ) Metrohm, Hyderabad 
15  UV – Spectrometer Shimadzu, Hyderabad 
16  HPLC   Watersalliance, Mumbai 
17  Disintegration Test Apparatus Electro lab, Hyderabad 
18  Rapid Mixer Granulator 
Sainath Boilers & Pneumatics, 
pune 
19  Electronic Sieve shaker SWECO, Hyderabad 
20  pH meter Polmon, Mumbai. 
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4.3 DRUG PROFILE 
PHYSICO- CHEMICAL PROPERTIES OF ACETAMINOPHEN60,61: 
TABLE -4 
 
S.NO CONTENTS ACETAMINOPHEN 
1 
Description  White crystalline powder having a slight 
bitter taste 
2 Synonym Acetaminophen  
3 Odour Odour less 
4 Chemical name N-(4-hydroxy phenyl)acetamide 
5 
Structure 
 
6 Molecular formula C8 H9 NO2 
7 Molecular weight 151.17g/mol 
8 
Solubility Very slightly soluble in cold water, 
considerably more in hot water. Soluble in 
methanol, acetone. 
9 Melting point 1690c 
10 Pka 9.51 at 250c 
11 
Stability Stable under ordinary conditions  of use & 
storage 
12 Half life 1-4hrs 
13 pH 4-7 PH Stable 
14 Log-P 0.4 
15 Wavelength 240-310nm 
16 Elimination half life 2-4hrs 
17 Cmax 0.5-3hrs 
18 Tmax 1-4hrs 
19 Volume of distribution 0.95L/kg 
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DESCRIPTION: 
 Acetaminophen is the active metabolite of phenacetin. Acetaminophen 
possesses analgesic and antipyretic activity however, some clinicians consider 
Acetaminophen a poor analgesic. Since Acetaminophen has no peripheral anti-
inflammatory activity, its efficacy as an analgesic may indeed be less than aspirin's in 
situations in which this action is desirable. Acetaminophen is preferred over aspirin as 
an analgesic/antipyretic for patients in whom aspirin is contraindicated, such as those 
who have a history of gastric ulcer or a coagulation disorder. Also, Acetaminophen 
does not interfere with the actions of uricosuric agents as aspirin can. Acetaminophen 
was first used in clinical medicine in 1893, but widespread use began after its FDA 
approval in 1950. It is available without a prescription as an individual agent in 
several dosage forms, and in combination with a variety of other drugs, although there 
is little evidence to show that therapeutic agents are more effective when combined 
with Acetaminophen. Recently, Acetaminophen has been implicated as a cause of 
renal disease. Sustained-release product, "Feverall Extended Release", was submitted 
for FDA approval 12/30/97. 
 
PHARMACOLOGY62: 
Acetaminophen is a popular analgesic and antipyretic drug that is used for the 
relief of fever, headaches, and other minor aches and pains. It is a major ingredient in 
numerous cold and flu medications and many prescription analgesics. It is extremely 
safe in standard doses, but because of its wide availability, deliberate or accidental 
overdoses are not uncommon. Acetaminophen unlike other common analgesics such 
as aspirin and ibuprofen has no anti inflammatory properties or effects on platelet 
function, and so it is not a member of the class of drugs known as non-steroidal anti-
inflammatory drugs or NSAIDs. In normal doses Acetaminophen does not irritate the 
lining of the stomach nor affect blood coagulation, the kidneys, or the fetal ductus 
arteriosus (as NSAIDs can). Like NSAIDs and unlike opioid analgesics, 
Acetaminophen does not cause euphoria or alter mood in any way. Acetaminophen 
and NSAIDs have the benefit of being completely free of problems with addiction, 
dependence, tolerance and withdrawal. Acetaminophen is used on its own or in 
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combination with pseudo ephedrine, dextromethorphan chlorpheniramine, 
Diphenhydramine, doxylamine, codeine, caffeine, hydrocodone, or oxycodone. 
 
Pharmacokinetics:  
Following oral administration, Acetaminophen is rapidly and almost 
completely absorbed from the GI tract. Peak plasma concentrations are attained within 
30-60 minutes, although serum concentrations and analgesia are not necessarily 
correlated. Binding to serum protein is about 25% after normal therapeutic dosages. 
  
Between 90-95% of the Acetaminophen dose is metabolized in the liver via 
glucuronidation and sulfate conjugation. At normal therapeutic doses, 94% of 
Acetaminophen is excreted in the urine as glutathione conjugates and only 2% as 
metabolites. After an acute overdose, conjugation of the hepatotoxic metabolite with 
glutathione is overwhelmed and hepatotoxicity occurs. At all doses, metabolites, but 
not unchanged drug, can accumulate in renal impairment. Plasma half-life is between 
1-2.5 hours in normal, healthy patients. After about 8 hours, only traces of the drug 
are detectable. Half-life can be prolonged in patients with hepatic disease, and, 
conversely, a prolonged half-life during an acute overdose can predict the subsequent 
development of hepatic necrosis.  
 
Dosage:  
• All dosage forms: Administer with a full glass of water.  
• Oral solution: Administer using a calibrated measuring device.  
• Oral suspension: Shake well before administration. Administer using a 
calibrated measuring device.  
• Chewable tablets: May be swallowed whole or chewed.  
• Oral granules: Mix with a small amount of soft food (i.e., applesauce, ice 
cream, or jam) prior to administration.  
• Oral powders: Do not administer the capsules containing the powder whole. 
Open capsule and sprinkle over a small amount of water (<5 ml) or mix with a 
small amount of soft food (i.e., applesauce, ice cream, or jam) prior to 
administration63. 
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Mechanism of Action: 
Acetaminophen is thought to act primarily in the CNS, increasing the pain 
threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, 
enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen 
does not inhibit cyclo-oxygenase in peripheral tissues and thus, has no peripheral anti 
inflammatory effects. While aspirin acts as an irreversible inhibitor of COX and 
directly blocks the enzyme’s active site, studies have found that acetaminophen 
indirectly blocks COX, and that this blockade is ineffective in the presence of 
peroxides. This might explain why acetaminophen is effective in the central nervous 
system and in endothelial cells but not in platelets and immune cells which have high 
levels of peroxides. Studies also report data suggesting that acetaminophen selectively 
blocks a variant of the COX enzyme that is different from the known variants COX-1 
and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action 
is still poorly understood, but future research may provide further insight into how it 
works. 
Contraindications:  
• Alcoholism  
• Anemia  
• Aspirin hypersensitivity  
• Hepatic disease  
• Hepatitis  
• Infection  
• Phenylketonuria  
• Renal impairment  
Drug Interactions with:  
• Antacids  
• Cimetidine  
• Ethanol  
• Phenobarbital  
• Phenothiazines  
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• Sulfinpyrazone  
• Warfarin  
Adverse Reactions:  
• Abdominal pain  
• Anemia  
• Elevated hepatic enzymes  
• Hemolysis  
• Hemolytic anemia  
• Hepatic necrosis 
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DIPHENHYDRAMINE HYDROCHLORIDE: 
PHYSICO-CHEMICAL PROPERTIES OF DIPHENHYDRAMINE HCl64: 
TABLE - 5 
S.NO CONTENTS DIPHEN HYDRAMINE 
1 Description White crystalline powder 
2 Synonym Diphenhydramine hydrochloride HCL 
3 Odour less Odour less 
4 
Chemical name 2-benzhydrolox –N,N-dimethyl-1-
ethanamine 
5 
 
 
 
Structure 
 
6 Molecular formula C17 H21 NO. Hcl 
7 Molecular weight 291.82g/mol 
8 Solubility Freely soluble in acetone alcohol, ether 
9 Melting point 166-1700c 
10 PKa 8.98 
11 
Stability Stable under ordinary conditions of use 
and storage 
12 Storage Preserve in tight, light resistant containers.  
13 Therapeutic Category Anti histamine 
14 CAS NO 58-73-1 
15 Ph Acidic range 4-6 
16 Log-p 3.27 
17 Wave length 215-258nm 
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Pharmacology65 
Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine 
antihistamines have significant antimuscarinic activity and produce marked sedation 
in most patients. In addition to the usual allergic symptoms, the drug also treats 
irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It 
also is used commonly to treat drug-induced extrapyramidal symptoms as well as to 
treat mild cases of Parkinson's disease. Rather than preventing the release of 
histamine, as do cromolyn and nedocromil, Diphenhydramine competes with free 
histamine for binding at HA-receptor sites. Diphenhydramine competitively 
antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large 
blood vessels, and bronchial muscle. Ethanolamine derivatives have greater 
anticholinergic activity than do other antihistamines, which probably accounts for the 
antidyskinetic action of Diphenhydramine. This anticholinergic action appears to be 
due to a central antimuscarinic effect, which also may be responsible for its antiemetic 
effects, although the exact mechanism is unknown. For the treatment of symptoms 
associated with Vertigo/Meniere's disease, nausea and vomiting, motion sickness and 
insect bite. 
 
Mechanism of action  
Diphenhydramine competes with free histamine for binding at HA-receptor 
sites. This antagonizes the effects of histamine on HA-receptors, leading to a 
reduction of the negative symptoms brought on by histamine HA-receptor binding. 
 
 
Pharmacokinetics: 
In Humans DiphenhydramineHCL is well absorbed after oral administration, 
but because of a relatively high first pass effect, only about 40-60% reaches the 
systemic circulation. Diphenhydramine is metabolized in the liver and the majority of 
the drug is excreted as metabolites in to urine. The terminal elimination half life in 
adult humans ranges from 2.4-9.3 hours. 
 
 
 
 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 46 
 
Drug Interaction: 
• Histamine H1 Antagonists  
• Anti-allergic Agents  
• Hypnotics and Sedatives  
• Antitussives  
• Antipruritics  
• Antiparkinson Agents  
• Antiemetics  
• Anasthetics 
Contraindications:   
• nausea  
• vomiting  
• motion sickness 
• insect bite 
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4.4 EXCIPIENTS PROFILE66 
TABLE - 6 
Pre gelatinized starch: 
Synonyms 
Compressible Starch, Lycatab C, Lycatab PGS, Mrigel, Starch 1500 G, 
Pharma Gel. 
Chemical Name Pregelatinized Starch 
Empirical Formula C6H10O5 
Molecular Weight 300-1000 
Functional Category Tablet and capsule diluent; tablet and disintegrant; tablet binder. 
Uses   
Use                                                 concentration (%) 
Diluent(hard gelatin capsule)                5-75                       
Tablet binder (direct compression)       5-20                              
Tablet binder (wet granulation)             5-10                                   
Tablet disintegrant                                 5-10    
Description 
Pregelatinized Starch occurs as a moderately coarse to fine, white to 
off-white colored powder. It is odorless and has a slight characteristic 
taste.Examination of Pregelatinized Starch as slurry in cold water, 
under a polarizing microscopic, reveals no significant ungelatinized 
granules, no “maltese crosses” characteristic of the starch birefringence 
pattern. 
Moisture Content Pregelatinized Starch is hygroscopic. 
Solubility 
Practically insoluble in organic solvents. Slightly soluble in cold water, 
depending upon the degree of pregelatinization. Pastes can be prepared 
by sifting the Pregelatinized Starch into stirred, cold water. Cold water-
soluble matter for partially Pregelatinized Starch is 10-20%. 
Safety 
Pregelatinized Starch and starch are widely used in oral solid dosage 
formulations. Pregelatinized Starch is generally regarded as a nontoxic 
and nonirritant excipient. However, oral consumption of massive 
amounts of Pregelatinized Starch may be harmful. 
Stability and Storage 
Conditions 
Pregelatinized Starch is a stable but hygroscopic material, which should 
be stored in a well-closed container in a cool, dry place. 
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TABLE – 7 
 
Microcrystalline Cellulose: 
 
Synonyms Celex, Avicel pH, crystalline cellulose  
Chemical Name  Cellulose 
 Empirical Formula (C6H10O5)n 
Functional Category Adsorbent, diluent, disintegrant 
Description 
It is purified, partially depolarized cellulose that occurs as white, 
odorless, crystalline powder composed of porous particles. 
Uses of MCC   
Use                                                 concentration (%) 
Adsorbent                                             20-90 
Antiadherent                                           5-20 
Capsule binder/diluent                       20-90 
Tablet disintegrant                                5-15 
Tablet binder/diluent                          20-90 
Melting Point 260-2700 C 
Moisture Content less than 5% 
Solubility 
Slightly soluble in 5% w/v hydroxide solution; practically 
soluble in water, dilute acids, and most organic solvents. 
stability and storage 
It is a stable through hygroscopic material. Bulk material should 
be stored in a well – closed container in a cool, dry place.  
Incompatibilities Incompatible with strong oxidizing agents 
Safety Non toxic and non irritant material 
Precautions  
It may be irritant to the eyes. So gloves, eye protection, and dust 
mask are recommended. 
Regulatory status  GRAS listed. 
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TABLE – 8 
Povidone K-3: 
 
Synonyms Kollidone, pvp, plasdone 
Chemical Name  1-Ethyl-2-pyrrolidinone homopolymer 
Empirical Formula (C6H9NO)n 
Functional Category Disintegrant, dissolution aid, suspending agent, tablet binder. 
Uses of Povidone 
Use                                                 concentration (%) 
Carrier for drugs                                     10-25 
Dispersing agent                                     up to 5 
Eye drops                                                2-10 
Suspending agent                                    upto5    
Tablet binder, tablet diluent,                    
 or coating agent                                       0.5-5 
Description 
It occurs as a fine, white to creamy – white colored, odorless or almost 
odorless, hygroscopic powder. 
Melting Point Softens at 150°C 
Moisture Content It is very hygroscopic  
Solubility 
Freely Soluble In Acids, Chloroform, Ethanol, ketone and Water; 
practically insoluble in ether, hydrocarbons, and mineral oil. 
Stability and storage 
conditions  
Povidone darkens to some extent on heating at 150°C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110-
130°C,steam sterilization of an aqueous solution does not alter its 
properties. 
Incompatibilities 
Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals. It forms molecular 
adducts in solution with sulfathiazole, sodium salicylate, salicylic acid, 
Phenobarbital, tannin, and other compounds. The efficacy of some 
preservatives, e.g. Thimersol, may be adversely affected by the formation 
of complexes with povidone. 
Safety 
It is nontoxic, nonirritant and it is not absorbed from the GI or mucous 
membranes. 
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TABLE – 9 
 
Stearic acid:      
       
 Synonyms Crodacid, Hystreme, Pristerene 
Chemical Name  Octadecanoic acid  
Empirical Formula C18H36O2 
Molecular weight 284.47g/mol 
Functional Category 
Emulsifying agent, solublizing agent, tablet & capsule 
lubricant.  
Concentration Used 
Ointment &creams-1-20% 
Tablet lubricant-1-3% 
Description 
 It is a hard, white or yellow colored, somewhat glossy, 
crystalline solid or a white or yellowish white powder. It has 
a slight odor & taste suggesting tallow.  
Melting Point ≥54oC 
Solubility 
Freely soluble in benzene, carbon tetrachloride, chloroform 
& ether; soluble in ethanol, PEG & hexane, practically 
insoluble in water.  
Incompatibilities 
It is incompatible with most metal hydroxides & may be 
incompatible with oxidizing agents. 
Safety Nontoxic 
Related substances Calcium stearate, Magnesium stearate, zinc stearate 
Stability and Storage 
Conditions 
Magnesium stearate is stable and should be stored in a well-
closed container in a cool, dry place. 
Stability And Storage 
Conditions 
 It is a stable material, an antioxidant may be added. 
Regulatory status 
Including in the FDA Ingredients Guide (oral capsules and 
tablets). 
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TABLE - 10 
 
Colloidal Silicon dioxide: 
 
Synonyms Aerosol, Cab-o-sil, colloidal silica. 
Chemical Name  Silica 
 Empirical Formula SiO2 
Functional Category Glidant, Adsorbent, Anticaking agent 
Description 
It is a light, loose, bluise-white collored, odorless, tasteless, 
nongritty amorphous powder. 
Uses of colloidal silicon 
dioxide 
 Use                                                 concentration (%) 
Aerosols                                             0.5-2.0 
Emulsion stabilizer                            1.0-5.0 
Glidant                                               0.1-0.5 
Suspending and thickening agent      2.0-10.0                                  
Solubility 
Practically insoluble in organic solvents, water, and acids, 
except hydrofluoric acid; soluble in hot solutions of alkali 
hydroxide. 
stability and storage It should be stored in a well closed  container 
Incompatibilities Incompatible with diethylstilboestrol preparations. 
Safety Non toxic and non irritant material. 
Precautions  
It may be irritant to the eyes. So gloves, eye protection, and dust 
mask are recommended. 
Regulatory status  GRAS listed. 
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TABLE -11 
 
Croscarmellose sodium: 
         
Synonyms Exploeel, Nymcelzsx, Pharmacel xl, Vivasol, Solutab. 
Functional Category Tablet and capsule disintegrate. 
Description 
  
Odorless, grayish white powder. 
Uses of croscarmellose 
sodium 
 Used as oral pharmaceutical formulation, disintegrate for 
capsule, tablet and granules. 
¾ For capsules 10-25 concentration  
¾ For tablet 0.5-5.0                                              
Solubility 
 Insoluble in water, partially insoluble in acetone, ethanol and 
toluene. 
stability and storage 
It is hygroscopic material, stored in well closed container in cool 
and dry place. 
Acidity PH= 5.0-7.0 in aqueous dispersion. 
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4.5 CONSTRUCTION OF STANDARD CURVE 
 
Standard preparation of acetaminophen: 
 Accurately weighed and quantitatively transferred 500mg of Acetaminophen 
to a 100 ml volumetric flask and it is dissolved in 10 ml of methanol.  5ml of 
Diphenhydramine HCl stock standard is pipetted to the volumetric flask, and 20 ml 
Mobile phase A is added, diluted to volume with Diluent, mixed well. The solution is 
stable for 48 hrs when stored at ambient conditions.67 
 
TABLE - 12 
 
Standard curve of Acetaminophen: 
 
S.NO Concentration Average peak area 
1 99.83 1202025 
2 149.74 1795911 
3 199.66 2436852 
4 249.57 3071035 
5 299.49 3626465 
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FIGURE – 1 
 
STANDARD CURVE OF ACETAMINOPHEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 55 
 
STANDARD CURVE OF DIPHENHYDRAMINE 
 
Diphenhydramine HCl stock standard: 
500mg Diphenhydramine hydrochloride is accurately weighed and 
quantitatively transferred to a 100 ml volumetric flask. 70 ml of diluent was added 
and sonicated for 15 min and volume is made.68 
 
TABLE – 13 
 
Standard curve of Diphenhydramine HCl: 
 
S.N Concentration Average peak area 
1 2.8 0820830 
2 5.6 1748992 
3 11.2 3283345 
4 16.8 4925730 
5 22.4 6566988 
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FIGURE – 2 
 
       Standard curve of Diphenhydramine HCl: 
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4.6 PRE FORMULATION STUDIES5 
 
Pre-formulation testing is an investigation of physical and chemical properties 
of a drug substances alone and when combined with excipients. It is the first step in 
the rational development of dosage forms. 
 
Description and solubility: 
Acetaminophen is white, odourless, crystalline powder. It is soluble in boiling 
water, 1N NaOH, freely soluble in alcohol. 
 
Diphenhydramine Hydrochloride is white, odourless, crystalline powder. It is 
freely soluble in water, alcohol, chloroform and slightly soluble in benzene and ether. 
 
Determination of bulk density and tapped density: 
The bulk density is ratio of the weight of the powder and volume it occupies. 
It is expressed as g/ml; bulk density is imparted in determining the size of the 
container needed for handling and processing. 
 
Procedure: 
An accurately weighed quantity of the Acetaminophen powder (W), was 
carefully poured into the graduated cylinder and the volume (Vo) was measured, then 
the graduated cylinder was closed with lid, set into the density determination 
apparatus. The density apparatus was set for 500 taps and after that, the volume (Vf) 
was measured and continued operation till the two consecutive readings were equal.  
The bulk density, and tapped density were calculated using the following formulas: 
                                            
  Bulk density   = W / Vo 
                                           Tapped density = W / Vf 
                                           Where, 
                                           W = weight of the powder 
                                           VO = initial volume 
                                           VF = final volume 
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Compressibility Index: 
 The compressibility 
index is indirectly related to relative 
flow rate, cohesiveness and 
particle size of the powder.  The 
compressibility index of material 
can be estimated from the tapped and bulk density of power.       
%Compressibility index = [(T.D – B.D) / T.D] 10 
Where T.D and B.D are bulk density and tap density respectively.        
 
 
TABLE – 14 
 
Carrs Index: 
 
COMPRESSIBILITY 
FLOW 
DESCRIPTION 
5-15 Excellent 
12-16 Good 
18-21 Fair 
23-28 Poor 
28-35 Poor 
35-38 Very poor 
>40 extremely poor 
                     
 
Hausners ratio:      
 
                
 
Housner’s Ratio Type of Flow 
Less than 1.25 Good Flow 
1.25-1.5 Moderate Flow 
More than 1.5 Poor Flow 
 
Hausners ratio Type of flow 
Less than 1.25 Good flow 
1.25-1.5                       Moderate flow 
More than 1.5       Poor flow 
Hausner’s ratio = Tapped Density 
      Bulk Density 
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Sieve analysis: 
 The main aim of sieve analysis is to determine the size of drug particles 
present. A series of standard sieves were stacked one above the other so that sieves 
with larger pore size (less sieve number) occupy top position followed by sieves of 
decreasing pore size (larger sieve number towards the bottom). 
 
 
Procedure:  
A series of sieves were arranged in the order of their decreasing pore diameter 
(increasing sieve number) i.e. sieve number 20, 40, 60, 80, 100, 120, 200, 325# and 
pan. 100 grams of drug was weighed accurately and transferred to sieve 20 which 
were kept on top. The sieves were shaken for about 5-10 minutes. Then the drug 
retained on each sieve was taken, weighed separately and amount retained was 
expressed in terms of cumulative percentage retained69. 
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4.7 DRUG EXCIPIENT COMPATIBILITY STUDIES 
Compatibility studies are carried out to study the possible interactions between 
Acetaminophen and Diphenhydramin Hydrochloride and other excipients. 
Procedure7: 
The compatibility studies were carried out by taking a mixture of drug and 
excipients at the ratio in which they are expected to be present in the innovator 
product. A part of mixture can be exposed to different storage conditions like 
40oC/75% RH and control samples were to be kept at 2-8oC. They were tested with 
respect to their physical and chemical aspects. 
 
TABLE - 15 
     Conditions for compatibility studies: 
S. NO CONDITIONS SAMPLES PACKED  IN 
SAMPLES 
OBTAINED AT 
1 
 
 
Accelerated 
40oC/75% RH 
 
 
3 Double polythene bags 
 
 
First week to 4th week. 
 
 
 
 
2 Refrigeration   2-8oC 
1 Double polythene bag + 1 
glass vessel 
First week to 4th week. 
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4.8 MANUFACTURING PROCEDURE 
 
Granulation: 
Dry Mixing:  
Acetaminophen had loaded into rapid mixing granulator along with 
microcrystalline cellulose mixed for 5 min at slow mixer speed. 
 
Preparation of Binder Solution: 
The binder was dissolved in hot Purified water. Then Stirred with stainless 
steel paddle until complete Povidone and Diphenhydramine Hydrochloride has 
transferred into solution. 
 
Wet Granulation: 
The binder was added into rapid mixing granulator while it mixed at slow 
mixer speed. Then extra water was added and until required consistency of mass was 
obtained.   
 
Drying: 
The FBP was started in manual mode & the process parameters are arranged.  
Wet granules were dried untill LOD of 0.3%w/w – 0.8 %w/w was achieved. (Actual 
limit established during the trials) The granules are then unloaded. All the parameters 
of fluid bed processor from the process record sheet were recorded.   
 
Sifting:  
The granules were sifted and dried through # 16 mesh.   
  
Blending and Lubrication:  
Blending:  
The sifted granules were loaded into Octagonal blender and blended with 
Croscarmellose- sodium, Stearic acid & aerosil for 5 min at 6 rpm. 
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Lubrication: 
Sifted Stearic acid was weighed and added into blender and lubricated for 10 
minutes at 8 rpm. 
 
Compression: 
 The blend was compressed into tablets using 19.2 X 6.00 mm punches and 
suitable dies with a tablet weight of 525mg.  
 
Coating:  
 The tablets were coated to get 2.0 % buildup by using 15% coating solution. 
The following parameters were maintained during coating: 
 
Inlet temp   - 60-70 oC 
Exhaust temp   - 40-50 oC 
Spray rate   - 6g/min. 
Spray pump rpm  - 6 
Atomization air pressure - 2.5Kg/cm2 
Gun to bed distance  - 11.5cm 
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4.9 COMPARATIVE DATA OF VARIOUS FORMULATIONS 
TABLE – 16 
 Formulation details in percentage: 
                Trial 
Ingredient  
T1 T2 T3 T4 T5 T6 T7 T8 T9 T1
0 
T1
1 
DRYMIX 
Acetaminophen 80.0 80.
0 
80.
0 
80.
0 
80.
0 
80.0
0 
80.
00 
80.
00 
80.
00 
80.
00 
80.
0 
Microcrystalline 
cellulose 
8.50 7.5
0 
7.5
0 
7.5
0 
7.0
0 
7.00 2.0
0 
2.0
0 
2.0
0 
2.0
0 
2.0
0 
BINDER 
PVP K-30 3.50 4.0 2.0
0 
2.5
0 
3.0 1.
60 
0.80 1.0 1.0 0.8
0 
0.8
0 
Pregelatinised 
starch 
- - - - - 2.
0 
10.2
0 
10.
20 
10.
20 
10.
20 
10.
20 
Diphenhydramine 
Hydrochloride 
4.0 4.0
0 
4.0
0 
4.0
0 
4.0
0 
4.
00 
4.00 4.0
0 
4.0
0 
4.0
0 
4.0
0 
LUBRICATION 
Croscarmellose 
sodium  
2.0 2.0
0 
3.5 3.0 3.0 3.0 1.0 1.0 1.0 1.0 1.0 
Polycrinilic 
potassium 
- - - 1.0 1.5
0 
1.0 - - - - - 
Stearic acid  - - - 1.40 1.5
0 
1.0 1.50 1.50 1.5
0 
1.5
0 
1.5
0 
Colloidal silicon 
dioxide 
- - 2.0 0.60 0.4
0 
0.4
0 
0.50 0.50 0.5
0 
0.5
0 
0.5
0 
Corn starch 1.0 1.0
0 
- - - - - - - - - 
Magnesium 
stearate 
1.0 1.5
0 
1.0 - - - - - - - - 
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4.10 EVALUATION OF GRANULES 
 
The granules were evaluated for tap density, Hausner ratio and Carr’s index as per 
standard procedures. 
4.11 EVALUATION OF TABLETS 
 
1. Description: 
About 20 tablets of sample were taken on a white porcelain plate and the 
description is observed. 
 
2. Identification by HPLC:  
The retention time of Acetaminophen and Diphenhydramine HCl peaks in the 
sample chromatogram of the assay preparation corresponds those in the 
chromatogram of the standard preparation as obtained in the assay. 
 
3. Average weight (mg) (In house method): 
20 tablets were randomly taken and weigh accurately. Then average weight is 
calculated. 
Average weight =weight of 20 tablets/ 20. 
 
4. Weight variation: 
20 tablets were weighed accurately and average weight was calculated. Then 
again the 20 tablets were individually weighed. The tablet which has highest weight 
and the tablet which has lowest weight was found out. Then the maximum and 
minimum deviations were calculated as follows.  The number of tablets that are 
deviated from the specification are noted. As per IP not more than two of individual 
weights should deviate from average weight by more than 5% and none deviate more 
than twice that percentage. 
 
5. Hardness (kp): 
The tablet was placed in between the jaws of hardness tester and the test was 
continued with a already arranged program for hardness determination and note down 
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the result and continued the test for 10 such tablets.  The valve displayed in kp for 
hardness is recorded. 
 
6. Disintegration time: 
One tablet each was placed in 6 tubes of the basket. This assembly was 
Suspend in water and maintained at temperature of 370C ± 20C and the apparatus is 
operated. The tablets were Observed, until last tablet gets disintegrated. The tablets 
pass the test, as all tablets have disintegrated in the specified time of the specification. 
The test is repeated as the failure of one or two tablets disintegrate completely. Not 
less than 16 of the total of 18 tablets tested should disintegrate completely. 
 
7. Dissolution by HPLC71: 
Solution A: 0.2 monobasic potassium phosphate(KH2PO4): 
About 27.22 gm of monobasic potassium phosphate was weighed and 1000 ml 
purified water is added and dissolved. 
 
Sodium solution B: 0.2 M hydroxide solution:  
About 0.8 gm of sodium hydroxide pellets are weighed in 100 ml volumetric 
flask and 60 ml of water was added and dissolved. The volume was made with 
purified water. 
 
Dissolution medium preparation (USP Phosphate buffer pH-5.8): 
250 ml of solution (A) was taken and added to 18 ml of solution (B),made up 
to the volume of 1000 ml with purified water . The pH was adjusted to 5.8± 0.05 with 
0.2 M sodium hydroxide solution if necessary.  
 
Dissolution parameters:  
Medium :  900ml phosphate Buffer pH 5.8  
Apparatus :  USP – type 2 (paddle) 
RPM  :  50  
Time  :  45 min 
Temperature :  37 ± 0.50C 
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Chromatographic conditions: 
Column  :  L10, 250×4.6 mm, 5µ (Inertsil-CN,250×4.6mm 
Wavelength  :  UV -220 nm  
Flow rate  :  2.0 ml per min 
Injection volume :  10μ L 
Run time  :  15 min 
 
Preparation of Buffer solution: 
  About 6.8 gms of mono basic potassium phosphate was weighed in 1000 ml of 
milli-Q water , 2 ml of Triethylamine was added  and  pH was adjusted to 4.0± 0.05 
with ortho phosphoric acid and filtered through 0.45 μm PVDF filter paper. 
 
Mobile phase Preparation: 
 940 ml of buffer solution was mixed with 60 ml of acetonitrile and filtered 
through 0.45µ m PVDF filter and degased. 
 
Diphenhydramine hydrochloride standard solution preparation: 
About 28 mg of diphenhydramine hydrochloride is accurately weighed and 
transferred into   100 ml volumetric flask, sufficient amount of dissolution medium is 
added and  sonicated to dissolve and make up to volume with dissolution medium. 
 
Standard preparation 
About 55 mg of acetaminophen is accurately weighed and transferred   into 
100ml volumetric flask, and added to 50 ml dissolution medium, sonicated to 
dissolve, to it  10 ml of diphenhydramine hydrochloride is added .Standard solution 
was stocked , mixed well and made up to volume with dissolution medium. (0.55 
mg/ml of acetaminophen and 0.028 mg/ml of diphenhydramine hydrochloride 
respectively).The solution is stable for 24 hrs when stored at ambient conditions. 
 
Sample preparation: 
One tablet was placed in  each of the 6 vessels containing 900 ml of the 
dissolution medium that has been equilibrated to 370C±0.5 0C. Care is taken to 
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exclude air bubbles from the surface of the tablet, apparatus is immediately operated 
with prescribed instrumental conditions for 45 minutes. 
 
10 ml of the sample solution is withdrawn after completion of the dissolution 
from a zone midway between the surface of the dissolution medium and the top of the 
rotating paddle, not less than 1cm from the vessel wall and filter through Millex-HV 
0.45 μm PVDF filter .The solution is stable for 24 hrs when stored at ambient 
conditions. 
 
Procedure:   
10 ml of the blank (dissolution media) is separately injected, standard 
preparation (5 replicate injections) and sample preparations into the chromatograph, 
chromatograms are recorded, and  responses for the major peaks are measured. The % 
release of Acetaminophen and Diphenhydramine HCl are calculated. 
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TABLE – 17 
 
 
Solutions into the HPLC system are injected following sequence: 
   
 
Injection  Name                  
 
Run 
time 
 
Number of 
injections 
Blank (dissolution media)
 
 
 
 
 
 
15 minutes 
 
 
 
 
 
Minimum of 1 
injection or until the 
base line stabilizes. 
 
 
5 Injections 
 
 
Dissolution standard 
1 Injection per sample 
 
 
   Dissolution sample 
 
 Inject after every 6 
samples injections or 
as per Bracketing 
standard SOP. 
 
Bracketing standard 
 
    
System suitability: 
Chromatograph the standard preparation and record the peak responses as directed. 
1. The % RSD of areas for five replicate injections of standard preparation shall 
not be more than 2.0%. 
2. Tailing factor of Acetaminophen and Diphenhydramine HCl peaks shall not be 
more than 2.0. 
3. The column efficiencies determined from the Acetaminophen and 
DiphenhydramineHCl peak shall not be less than 2000 theoretical plates.   
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Calculations:                                                               
% of Acetaminophen:                   % of Diphenhydramine HCl: 
 
   TA         SW       900                 
---------X ------- X  ------X P 
   SA        100        L.A               
 TA        SW      10      900 
-------X-------X------X------X P 
SA       100      100     L.A 
 
                          
Where,  
SA = Area/ response due to Acetaminophen in standard preparation. 
TA = Area /response due to Acetaminophen in sample preparation 
SW = Weight of Acetaminophen working standard in mg 
     P = Potency of Acetaminophen working standard. 
L.A = Labeled amount of Acetaminophen in mg. 
 
Assay by HPLC: 
Mobile phase A:  
Weighed and dissolved about 6.8 gm monobasic potassium phosphate 
1000mL of milli-Q water, and it is adjusted to pH to 4.5 ± 0.05 with orthophosphoric 
acid or sodium hydroxide. Filtered through 0.45-µm PVDF filter paper. 
 
Mobile phase B: 
Acetonitrile. 
 
Diluent: 
Milli-Qwater. 
 
Chromatographic conditions: 
Column         : Phenomenex Columbus C8, 150mm x 4.6 mm, 5mm x 4.6 
mm,  5μ, EO or phenomenex Luna C8(2),150MM X 
4.6MM, 5µ.  
Guard column: Phenomenex security guard with a 4.0 mm L x 3.0mm ID C8 
catridge. 
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Wavelength : 300 nm switching to 225 nm at 4 min or run dual wavelength 
  Flow rate    : 1.5ml/minute 
Injection volume: 5µL 
Run time: 8 minutes 
Column temperature: 35oC. 
 
TABLE – 18 
 
 
TIME(min) 
 
 
Flow rate 
(Ml/min) 
 
Mobile phase 
A 
 
 
Mobile phase B 
 
 
Curve 
 
 
0.00 
 
1.5 
 
85.0 
 
15.0 
-- 
 
 
5.00 
 
1.5 
 
45.0 
 
55.0 
 
6 
5.10 1.5 85.0 15.0 6 
8.00 
 
1.5 
 
85.0 
 
15.0 
 
6 
 
 
 
Standard preparation of acetaminophen: 
Accurately weighed and quantitatively transferred 500mg of Acetaminophen 
WS to a 100 ml volumetric flask and it is dissolved in 10 ml of Methanol. 5ml of 
Diphenhydramine HCl stock standard is pipetted to the volumetric flask, 20 ml 
Mobile phase A is added and diluted to volume with Diluent, mixed well. The 
solution is stable for 48 hrs when stored at ambient conditions. 
 
Diphenhydramine HCl stock standard: 
Accurately weighed and quantitatively transferred 500 mg Diphenhydramine 
HCl to a 100 ml volumetric flask. 70 ml of Diluent is added and sonicated for 15 min 
or until dissolved. Diluted to volume with diluent and mixed well. 
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Sample preparation: 
Accurately weighed and tablets are added in to 1000 ml volumetric flask. 100 
ml of water, 100 ml of methanol and 200 ml of mobile phase A is added. Sonicated 
for 30 minutes. 2 ml of concentrated phosphoric acid is added, swirl and to return to 
room temperature. The flask is diluted to volume with diluents. Mixed thoroughly.  
This preparation is filtered through a 0.45μm pore size membrane filter, discarding 
atleast the first 2 ml of the filterate. The solution is stable for 48hrs when stored at 
ambient conditions. 
 
Procedure:  
5µl of the blank (mobile phase A)is separately injected until the suitable base 
line is established.Working standard(5 replicate injections) and working sample is 
injected into the chromatograph,  chromatograms are recorded, and  responses for the 
major peaks are measured.  The percentage of Acetaminophen and Diphenhydramine 
hydrochloride are calculated.  
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TABLE - 19 
 
INJECTION NAME 
 
 
RUN 
TIME 
 
NUMBER OF 
INJECTIONS 
 
Blank (mobile phase 
A) 
 
 
 
    
 
 
 
8 minutes 
 
 
 
 
 
 
 
 
 
 
Minimum of 1 injection or until 
the line stabilizes. 
 
 
 
5 injections 
 
 
 
Standard 
 
¾ 1 injection per sample 
for uniformity of dosage 
form. 
¾ 2 injections per sample 
for Assay 
 
 
 
     
 
Sample 
 
 
 
Bracketing 
standard 
 
As per bracketing 
standard  SOP 
        
System suitability: 
1. The 5% of area for 5 replicate injections of both Acetaminophen and 
Diphenhydramine from standard preparation shall not be more than 2.0. 
2. Tailing factor of Acetaminophen and Diphenhydramine HCl peaks shall not be 
more than 2.0. 
3. The column efficiencies determined from the Acetaminophen and 
Diphenhydramine HCl peak shall not be less than 2000 theoretical plates.  
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Calculation: 
% of Acetaminophen:                                                
 
                                 TA         SW       1000                     P         100 
                            ---------X ------- X  ------X Ave. wt. x ------- X  -------       
                                 SA          100      TW                     100         L.A 
 
 
% of Diphenhydramine HCl(% of LA):                                                
 
                                 TA         SW     5     1000                        P           100 
                            ---------X ------- X----X ------X Ave. wt. x ------- X  -------       
                                 SA          100    100   TW                      100           L.A 
Where,  
SA  =  Area/ response due  to Acetaminophen in standard preparation. 
TA =  Area /response due to Acetaminophen in sample preparation 
SW =  Weight of  Acetaminophen working standard in mg 
P  = Potency of Acetaminophen working standard. 
L.A = Labeled amount of Acetaminophen in mg. 
T.W= Weight of sample taken in mg 
Ave.wt = Average weight of the tablet in mg 
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4.12 DISSOLUTION PROFILE COMPARISON USING f1 f2 
FACTORS 
 
                    f1=Dissimilarity factor 
                    f2=Similarity factor 
 
A dissolution profile can characterize the product more precisely than a single 
point dissolution test. It helps to assure similarity in product performance and signals 
bioequivalence. The factor f1 is proportional to the average indifference between two 
profiles, where as factor f2 inversely proportional to the average squared indifference 
between two profiles. The factor f2 measures the closeness between two profiles, 
FDA has set a public standard of f2 value between 50-100 to indicate similarity 
between two profiles. 
 
   f1 = ΣD(1/ Σt) 100 
             f2 = 50 x ln{1/91+Σ (Rt-Tt)2} 
 
Procedure: 
Mean dissolution values of the two profiles (test and innovator) are taken and 
they are made under same test conditions and same time points. The time points taken 
as 2, 4, 6, 10, 15,20, 30,35 and 45 minutes. The following mathematical approach is 
made to compare the dissolution profiles of Acetaminophen and Diphenhydramine 
HCl tablets using two factors f1 and f2.   
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4.13  STABILITY STUDIES  
  
Stability studies are an integral part of the drug development program & are 
one of the most important areas in the registration of pharmaceutical products. The 
purpose of stability testing is to provide evidence on how the quality of a drug 
substances or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity & light and enables 
recommended storage conditions, re-test periods and shelf half lifes to be established. 
Stability assessment starts with studies on the substances to determine degradation 
products degradation pathway. In these type of studies the product is analyzed at 
intervals for various parameters which may include assay of active ingredient, 
measurement of known degradation products, hardness, disintegration time, 
dissolution time, appearance, etc., Acetaminophen 500mg and Diphenhydramine 
Hydrochloride 25mg tablets were evaluated for their stability by means of accelerated 
stability studies at 40ºC/75% RH, 25ºC/60% RH conditions72.  
Storage conditions: 40ºC/75%RH, 25ºc/60% RH 
Packs: Unit pack & bulk pack 
Period: 1, 2, and 3 months. 
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5. RESULTS AND DISCUSSION 
 
5.1 Preformulation parameters: 
The various preformulation factors are evaluated and found to be 
satisfactory within the limits prescribed. 
 
The results are tabulated in below. 
 
TABLE - 20 
Blend properties 
 
Formula 
 
Bulk density 
g/mL(untapped)
 
Tap 
density(g/mL)
 
Angle of 
repose(ө) 
 
Compressibility 
or Carr’s index 
 
Hausner’s 
ratio 
1 0.575±0.065 0.757±0.053 36.34±0.9 24.04±0.31 1.31±0.02
2 0.328±0.076 0.403±0.059 24.93±0.93 18.61±0.36 1.22±0.04
3 0.324±0.079 0.403±0.061 30.35±0.95 19.60±0.39 1.24±0.06
4 0.327±0.082 0.401±0.065 32.53±0.98 18.45±0.43 1.22±0.081
5 0.336±0.085 0.397±0.069 29.56±0.1 15.36±0.48 1.18±0.09
6 0.341±0.089 0.402±0.073 29.85±0.13 15.17±0.54 1.17±0.13
7 0.343±0.093 0.399±0.078 28.86±0.14 14.03±0.58 1.14±0.15
8 0.347±0.096 0.412±0.082 29.02±0.16 15.77±0.67 1.18±0.17
9 0.340±0.115 0.401±0.086 28.46±0.17 15.21±0.74 1.17±0.19
10 0.337±0.120 0.398±0.091 29.91±0.18 15.32±0.78 1.18±0.20
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Sieve analysis:  
 
PARTICLE SIZE % CUM. RETENTION 
20# 0.1
40# 2.9
60# 11.4
80# 26.0
100# 32.9
200# 9.5
325# 71.0
Pan 19.5
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5.2 FORMULATION DEVELOPMENT 
TRIAL 1 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg tablets. 
II. Batch size: 2.0 kg. 
III. Formula 
TABLE – 21 
 
      Formula for Trial 1 
S.No INGREDIENTS 
QUANTITY 
(%) 
QUANTITY 
(mg) 
1 Acetaminophen 80.0 420.00 
2 Microcrystalline cellulose 8.50 44.625 
3 Povidone K-30 3.50 18.375 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Water q.s q.s 
6 Croscarmellose sodium 2.00 10.50 
7 Magnesium stearate 1.00 5.25 
8 Corn starch 1.00 5.25 
 
 
IV. Procedure: Wet granulation   procedure was followed. 
V. Observation/Conclusion: Big lumps were formed during granulation, 
          Poor flow of granules was observed. 
VI. Further Plan of action:Next batch is planned with increased binder and 
glidant concentrations. Microcrystalline cellulose concentration is decreased.  
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TRIAL 2 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine       
           hydrochloride 25 mg Tablets. 
II. Batch size: 2.0 kg. 
III. Formula 
 
TABLE – 22 
 
 Formula for Trial 2 
S.No INGREDIENTS 
QUANTITY 
(%) 
QUANTITY(mg) 
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 7.50 39.375 
3 Povidone k-30 4.00 21.0 
4 Diphenhydramine Hydrochloride 4.00 21.0 
5 Water q.s q.s 
6 Croscarmellose sodium 2.00 10.5 
7 Magnesium stearate 1.00 8.4 
8 Corn starch 1.50 7.35 
 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Conclusion: Small lumps are formed, Poor flow of granules, 
more disintegration time than intended. 
VI. Further Plan of action: Next batch with increased disintegrant concentration 
and change of glidant. 
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TRIAL 3 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25mg tablets. 
II. Batch size: 2.0 kg. 
III.  Formula 
 
TABLE - 23 
Formula for Trial 3 
S.No               INGREDIENTS QUANTITY 
(%) 
QUANTITY(mg) 
1 Acetaminophen 80.0 420.00 
2 Microcrystalline cellulose 7.50 39.375 
3 Povidone k-30 2.00 10.50 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Water q.s q.s 
6 Croscarmellose sodium 3.50 18.375 
7 Magnesium stearate 1.00 5.25 
8 Colloidal silicon dioxide 2.00         10.50 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Conclusion: Better disintegration time but flow is not good and 
sticking was observed. 
VI. Further Plan of action: Next batch is planned with another disintegrant along 
with croscarmellose sodium and stearicacid instead of magnesium stearate. 
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TRIAL 4 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25mg tablets. 
II. Batch size: 2.0 kg. 
III.  Formula 
 
TABLE – 24 
 
          Formula for Trial 4 
S.No INGREDIENTS QUANTITY (%) QUANTITY(mg)
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 7.50 39.375 
3 Povidone k-30 2.50 13.125 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Water q.s q.s 
6 Croscarmellose sodium 3.00 15.75 
7 Polycrinilic potassium 1.00 5.25 
8 Stearic acid 1.40 7.35 
9 Colloidal silicon dioxide 0.60 3.15 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Conclusion: Disintegration time increased. 
VI. Further plan of action: Next batch is planned by changing the proportions of 
disintegrants. 
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TRIAL 5 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25mg tablets. 
II. Batch size: 2.0 kg. 
III.  Formula 
           
TABLE -25 
 
      Formula for Trial 5 
S.No INGREDIENTS QUANTITY (%) QUANTITY(mg)
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 7.00 36.75 
4 Povidone k-30 3.00 15.75 
5 Diphenhydramine Hydrochloride 4.00 21.00 
6 Water q.s q.s 
7 Croscarmellose sodium 3.00 15.75 
8 Polycrinilic potassium 1.00 5.25 
9 Stearic acid 1.40 7.35 
10 Colloidal silicon dioxide 0.60 3.15 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Inference: Disintegration is good but Rat holing of blend in the 
hopper. 
VI. Further plan of action:  Next batch with Pregelatinized maize starch in 
binder is planned. 
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TRIAL 6 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg tablets. 
II.  Batch size: 2.0 kg. 
III.  Formula 
TABLE – 26 
 
     Formula for Trial 6 
S.No INGREDIENTS QUANTITY (%) QUANTITY(mg)
1 Acetaminophen 80.00 420 
2 Microcrystalline cellulose 7.00 36.75 
3 Povidone k-30 1.60 8.4 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Pregelatinized starch 2.00 10.50 
6 Water q.s q.s 
7 Croscarmellose sodium 3.00 15.75 
8 Polycrinilic potassium 1.00 5.25 
9 Stearic acid 1.00 5.25 
10 Colloidal silicon dioxide 0.40 2.1 
 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Inference: Coarser granules are obtained but disintegration is 
beyond the required range. 
VI. Further plan of action: Next batch is planned by removing the Polycrinilic 
potassium, reducing the microcrystalline cellulose concentration and increases 
concentration of Pregelatinized starch. 
 
 
 
 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 84 
 
TRIAL 7 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg tablets. 
II. Batch size: 2.0 kg. 
III.  Formula 
       
TABLE -27 
 
      Formula for Trial 7 
S.No INGREDIENTS 
QUANTITY 
(%) 
QUANTITY(mg) 
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 2.00 10.50 
3 Povidone k-30 0.80 4.2 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Pregelatinized starch 9.20 48.3 
6 Water q.s q.s 
7 Croscarmellose sodium 1.00 5.25 
8 Pregelatinized  starch 1.00 5.25 
9 Stearic acid 1.50 7.875 
10 Colloidal silicon dioxide 0.50 2.625 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Inference: All the compression parameters are good.  
VI. Further plan of action: Next batch with the same formula is planned for film 
coating. 
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TRIAL 8 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg Tablets. 
II. Batch size: 2.0 kg. 
III. Formula 
 
TABLE – 28 
 
    Formula for Trial 8 
S.No INGREDIENTS QUANTITY (%) QUANTITY(mg) 
1 Acetaminophen 80.00 420 
2 Microcrystalline cellulose 2.00 10.50 
3 Povidone k-30 0.80 4.2 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Pregelatinized starch 9.20 48.3 
6 Water q.s q.s 
7 Croscarmellose sodium 1.00 5.25 
8 Pregelatinized  starch 1.00 5.25 
9 Stearic acid 1.50 7.875 
10 Colloidal silicon dioxide 0.50 2.625 
11 Opadry 13B88093 Blue 2.00 10.50 
 
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Inference: Orange peel effect was observed. 
VI. Further plan of action: Next batch is planned with same coating material and 
procedure with increase in drying temperature.   
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TRIAL 9 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg tablets. 
II. Batch size: 2.0 kg. 
III. Formula 
TABLE -29 
 
     Formula for Trial 9 
S.No INGREDIENTS 
QUANTITY 
(%) 
QUANTITY(mg) 
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 2.00 10.50 
3 Povidone k-30 0.80 4.2 
4 Diphenhydramine Hydrochloride 4.00 21.00 
  5 Pregelatinized starch 9.20 48.30 
   6 Water q.s q.s 
   7 Croscarmellose sodium 1.00 5.25 
  8 Pregelatinized  starch 1.00 5.25 
9 Stearic acid 1.50 7.875 
10 Colloidal silicon dioxide 0.50 2.625 
11 Opadry 13B88093 Blue 2.00 10.50 
.  
IV. Procedure: Wet granulation procedure was followed. 
V. Observation/Inference: Coating parameters are found to be good. 
VI. Further plan of action: Two batches are planned with same formula for 
reproducibility of results and for checking dissolution profile.  
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TRIAL 10 & 11 
 
I. Objective: To manufacture Acetaminophen 500mg and Diphenhydramine 
hydrochloride 25 mg tablets. 
II. Batch size: 2.0 kg. 
III. Formula 
TABLE – 30 
 
    Formula for Trial 10 & 11 
S.No INGREDIENTS 
QUANTITY 
(%) 
QUANTITY(mg) 
1 Acetaminophen 80.00 420.00 
2 Microcrystalline cellulose 2.00 10.50 
3 Povidone k-30 0.80 4.2 
4 Diphenhydramine Hydrochloride 4.00 21.00 
5 Pregelatinized starch 9.20 48.3 
6 Water q.s q.s 
7 Croscarmellose sodium 1.00 5.25 
8 Pregelatinized  starch 1.00 5.25 
9 Stearic acid 1.50 7.875 
10 Colloidal silicon dioxide 0.50 2.625 
11 Opadry 13B88093 Blue 2.00 10.50 
 
IV. Procedure: wet granulation procedure was followed. 
V. Observation/Inference: Desired compression and coating tablet parameters 
are observed. 
VI. Further plan of action: The two batches are planned for stability studies. 
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5.3COMPRESSION PARAMETERS 
 
Compress the blend into tablets by using 19.5 X 6.03mm punches and suitable dies. 
TABLE - 31 
Compression parameters 
 
COATED TABLET PARAMETERS: 
 Coated tablet parameters 
 
 
 
 
 
 
 
 
 
  
 
 
TEST T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 
Tablet weight 570 570 570 570 610 620 620 620 640 640 
Hardness 
(Kp) 
10.0± 
0.12 
10.5± 
0.35 
10.9± 
0.21 
10.9± 
0.17 
10.9± 
0.15 
11.2± 
0.24 
11.4± 
0.25 
11.0± 
0.09 
11.2± 
0.08 
11.7± 
0.13 
Thickness-mm 5.08± 
0.008 
5.09± 
0.007 
5.07± 
0.005 
5.20± 
0.010 
5.18± 
0.009 
5.19± 
0.009 
5.21± 
0.010 
5.50± 
0.025 
5.50± 
0.025 
5.50± 
0.025 
Disintegration 
time –min 
1.28 1.00 0.48 0.34 1.26 0.47 0.46 2.24 2.44 2.37 
Friability -
%w/w 
0.60± 
0.023 
0.17± 
0.013 
0.17± 
0.013 
0.17± 
0.013 
0.16± 
0.012 
0.16± 
0.012 
0.12± 
0.006 
0.11± 
0.006 
0.21± 
0.010 
0.16± 
0.012 
Weight 
variation-mg 
570± 
2.64 
565± 
2.62 
566± 
2.63 
565± 
2.63 
585± 
2.72 
607± 
2.82 
601± 
2.80 
592± 
2.76 
608± 
2.81 
608± 
2.81 
TEST T09 T10 T11 
Hardness-kp 11.0±0.09 11.2±0.08 11.7±0.13 
Thickness-mm 5.50±0.025 5.50±0.025 5.50±0.025 
Disintegration time –min 2.24 2.44 2.37 
Weight variation-mg  592±2.76 608±2.81 608±2.81 
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5.4 COMPATABILITY STUDIES 
TABLE – 32 
 
       FTIR OF ACETAMINOPHEN 
S.NO 
PEAK 
AREA(cm-1) 
MODE OF 
VIBRATION 
1 3326 O-H Stretching 
2 3161 N-H Stretching 
3 1610-1563 Aromatic Stretching 
4 1226-1171 C-0 Stretching 
5 
796 Aromatic C-H out 
plain bending 
 
FIGURE - 3 
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TABLE - 33 
 
  FTIR of DiphenhyDamine Hydrochloride: 
S.NO 
PEAK 
AREA(cm-1) 
MODE OF 
VIBRATION 
1 3032 Aromatic C-H Stretching 
2 2896 Aliphatic C-H Stretching 
3 1108-1019 C-H Bending 
4 
882 Aromatic C-H out of 
plain bending. 
 
 
FIGURE - 4 
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FTIR OF ACETAMINOPHEN + DIPHENHYDRAMINE + CCS 
FIGURE - 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REPORT: 
These results indicated that there is no chemical interaction 
between drug and excipients when formed as tablet. 
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TABLE – 34 
 
S 
NO 
NAME OF 
THE 
EXCIPIENT 
CATEGORY COMPATIBILITY STATUS 
1 
Microcrystalline 
cellulose MCC) 
Diluent
 
Compatible
 
2 
Pregelatinised 
Starch (PGMS) 
Diluent/Binder Compatible 
3 Povidone K-30 Binder Compatible 
4 
Croscarmellose 
sodium 
Disintegrant
 
Compatible
 
5 
Colloidal silicon 
dioxide 
Glident Compatible 
6 Stearic acid Lubricant Compatible 
7 Purified Water Vehicle Compatible 
8 
Opadry 
13B80923 Blue 
Coating 
material 
Compatible 
 
Report: 
These result indicated that there is no chemical interaction between drug and 
excipients when formed as tablets. 
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5.5 IN-VITRO RELEASE STUDIES 
Innovator 
Dissolution medium  :  Purified water 
Volume of medium   :  900ml 
Apparatus                  : USP-II (Paddle Type) apparatus. 
Speed (RPM)             :  50 
Temperature               :  37oC ±0.5oC 
Sampling points         :  5, 10, 15, 20, 25, 30, 30, 35,40and 45. 
Result: 
TABLE – 35 
 
Innovator dissolution profile. 
 
S.NO TIME (min) 
CUMULATIVE % 
ACETAMINOPHEN 
CUMULATIVE % OF 
DIPHENHYDRAMINE 
1 5 31.9 19.3 
2 10 67.3 57.8 
3 15 78.5 72.4 
4 20 82 79.3 
5 25 88.2 84.5 
6 30 89.4 89.1 
7 35 92.5 92.7 
8 40 94.0 95.0 
9 45 95.5 96.8 
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Graph: 
 
 
 
 
FIGURE – 6 
 
INNOVATOR DISSOLUTION PROFILE. 
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TABLE – 36 
 
In vitro drug release profile of Acetaminophen and Diphenhydramine.HCl 
tablet formulation: 
Formulation 9: 
S.NO TIME (min) 
CUMULATIVE % 
ACETAMINOPHEN 
CUMULATIVE % OF 
DIPHENHYDRAMINE 
1 5 34.9 28.7 
2 10 76.4 79.8 
3 15 85.9 88 
4 20 92.4 91.1 
5 25 93.6 93.2 
6 30 94 94.8 
7 35 94.7 96.3 
8 40 96.2 97.0 
9 45 97.2 97.9 
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FIGURE – 7 
 
IN VITRO DRUG RELEASE PROFILE OF ACETAMINOPHEN AND 
DIPHENHYDRAMINE 
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TABLE – 37 
 
In vitro drug release profile of Acetaminophen and Diphenhydramine 
hydrochloride tablets formulation: 
 
Formulation 10: 
S.NO TIME (min) 
CUMULATIVE % 
ACETAMINOPHEN 
CUMULATIVE % OF 
DIPHENHYDRAMINE 
1 5 34.2 22.8 
2 10 69.7 59.1 
3 15 80.1 73.6 
4 20 84.3 81.4 
5 25 89.8 86.3 
6 30 92.6 90.4 
7 35 92.8 93.8 
8 40 96.0 94.0 
9 45 98.6 98.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 98 
 
 
 
 
 
 
 
FIGURE - 8 
 
IN VITRO DRUG RELEASE PROFILE OF ACETAMINOPHEN AND 
DIPHENHYDRAMINE HYDROCHLORIDE 
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TABLE – 38 
 
In vitro drug release profile of Acetaminophen and Diphenhydramine 
hydrochloride tablet formulation: 
 
Formulation 11: 
S.NO TIME (min) 
CUMULATIVE % 
ACETAMINOPHEN 
CUMULATIVE % OF 
DIPHENHYDRAMINE 
1 5 33.9 22.3 
2 10 87.6 80.7 
3 15 94.2 85.4 
4 20 95.7 88.2 
5 25 96.7 89.5 
6 30 97.5 90.4 
7 35 98.1 91.4 
8 40 98.5 95.0 
9 45 99.7 98.5 
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FIGURE – 9 
 
IN VITRO DRUG RELEASE PROFILE OF ACETAMINOPHEN AND 
DIPHENHYDRAMINE HYDROCHLORIDE 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   Formulation and evaluation of Acetaminophen and Diphenhydramine hydrochloride tablets 
 
K.M.College of Pharmacy           page 101 
 
COMPARATIVE DISSOLUTION STUDIES: 
Dissolution was carried out at following conditions  
Dissolution medium: Purified water 
Volume of medium   :  900ml 
Apparatus                  : USP-II (Paddle Type) apparatus. 
Speed (RPM)             :  50 
Temperature              :  37oC ±0.5oC 
Sampling points        : 5, 10, 15, 20, 25, 30, 35,40 and 45 minutes. 
 
TABLE - 39 
   
 Comparative dissolution profile: 
 
Time 
(min) 
Innovator 
%Drugrelease 
Trail 9 Trail 10 Trail 11 
APAP DPHCl APAP DPHCl APAP DPHCl APAP DPHCl
5 31.9 19.3 34.9 28.7 34.2 22.8 33.9 22.3 
10 67.3 57.8 76.4 79.8 69.7 59.1 87.6 80.7 
15 78.5 72.4 85.9 88.0 80.1 73.6 94.2 85.4 
20 82.0 79.3 92.4 91.1 84.3 81.4 95.7 88.2 
25 88.2 84.5 93.6 93.2 89.8 86.3 96.7 89.5 
30 89.4 89.1 94.0 94.8 92.6 90.4 97.5 90.4 
35 92.5 92.7 94.7 96.3 92.8 93.8 98.1 91.4 
40 94.00 95.00 96.2 97.00 96.0 94.00 98.5 95.00 
45 95.5 96.8 97.2 97.9 98.6 98.1 99.7 98.5 
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Graphs: 
 
 
FIGURE – 10 
 
COMPARATIVE DISSOLUTION PROFILE OF ACETAMINOPHEN 
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FIGURE - 11 
 
COMPARATIVE DISSOLUTION PROFILE OF 
DIPHENHYDRAMINE HYDROCHLORIDE 
 
                     
 
 
 
 
 
 
 
 
 
                                                           
 
 Discussion: 
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FORMULATION F9:  
The Invitro dissolution was low in Acetaminophen i.e., 97.2% and 
Diphenhydramine hydrochloride was 97.9% respectively at the end of 45 minutes. 
Hence another formulation is done. 
  
FORMULATION F10:  
The Invitro dissolution of Acetaminophen was 98.6% and Diphenhydramine 
hydrochloride was 98.1% respectively at the end of 45 minutes. The drug release in 
the 10th formulation was good but to know the further drug release another 
formulation was done. 
 
FORMULATION F11:  
The Invitro drug release profile of optimized formula of Acetaminophen was 
99.7% and diphenhydramine hydrochloride was 98.5%. The formula was compared 
with innovator product and it was found that the drug release was more in the 
formulation F11 so it was selected as best formulation. 
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TABLE – 40 
 
 
Dissolution by HPLC: Acetaminophen: 
 
S.N Name Vial Injection Retention time 
Area(μV 
sec) 
% 
Area 
Height 
(μV) 
% 
Height
Sample 
ID 
1 Acetaminophen 2 1 3.058 5196656 94.97 643310 98.34 Std 
2 Acetaminophen 2 1 3.055 5119333 94.88 640328 98.32 Std  
3 Acetaminophen 2 2 3.058 5173326 95.00 641917 98.35 Std 
4 Acetaminophen 2 3 3.063 5200779 95.06 640827 98.35 Std 
5 Acetaminophen 2 4 3.062 5192686 94.95 639005 98.34 Std 
6 Acetaminophen 2 5 3.064 5180926 95.02 637093 98.35 Std 
Mean    3.060 5177284     
Std.Dev    0.00 30172.0     
% RSD    0.11 0.58     
  
TABLE - 41 
 
Diphenhydramine Hcl: 
 
S.N Name Vial Injection Retention 
time 
Area(μV 
sec) 
% 
Area 
Height 
(μV) 
% 
Height
Sample 
ID 
1 D.P HCl 2 1 9.455 275180 5.03 10888 1.66 Std 
2 D.P HCl 2 1 9.429 276288 5.12 10930 1.68 Std 
3 D.P HCl 2 2 9.467 272513 5.00 10778 1.65 Std 
4 D.P HCl 2 3 9.477 270424 4.94 10740 1.65 Std 
5 D.P HCl 2 4 9.480 276460 5.05 10790 1.66 Std 
6 D.P HCl 2 5 9.485 271317 4.98 10692 1.65 Std 
Mean    9.465 273697     
Std.Dev    0.02 2620.0     
% RSD    0.22 0.96     
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TABLE – 42 
 
Dissolution by HPLC: Acetaminophen Sample: 
 
S.N Name Vial Injection Retention time 
Area(μV 
sec) 
% 
Area 
Height 
(μV) 
% 
Height
Sample 
ID 
1 Acetaminophen 33 1 3.050 5120650 94.97 641149 98.35 sample 
2 Acetaminophen 34 1 3.050 5097151 94.88 637560 98.36 sample 
3 Acetaminophen 35 1 3.049 5114663 95.00 640683 98.36 sample 
4 Acetaminophen 36 1 3.049 5102620 95.06 639074 98.36 sample 
5 Acetaminophen 37 1 3.051 5108731 94.95 640646 98.37 sample 
6 Acetaminophen 38 1 3.053 5099698 95.02 639000 98.36 Sample 
Mean    3.060 5107252     
Std.Dev    0.00 9134.4     
% RSD    0.05 0.58     
 
 
TABLE – 43 
 
Dissolution by HPLC: Diphenhydramine HCl Sample: 
  
S.N Name  Vial Injection Retention 
time 
Area(μV 
sec) 
% 
Area 
Height 
(μV) 
% 
Height
Sample 
ID 
1 D.P HCl 
33 1 9.396 269306 5.00 10724 1.65 sample 
2 D.P HCl 
34 1 9.397 267184 4.98 10635 1.64 sample 
3 D.P HCl 
35 1 9.400 268283 4.98 10688 1.64 sample 
4 D.P HCl 
36 1 9.396 268132 4.99 10680 1.64 sample 
5 D.P HCl 
37 1 9.406 267041 4.97 10633 1.63 sample 
6 D.P HCl 
38 1 9.420 267937 4.99 10633 1.64 Sample 
Mean    9.403 267981     
Std.Dev    0.01 823.4     
% RSD    0.10 0.31     
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TABLE - 44 
Calculation Acetaminophen: 
 No. of standard replicates: 
 
 
INJECTION Area 
Injection  1 5196656.60000 
Injection 2 5778322.60000 
Injection 3 5200779.60000 
Injection 4 5192086.60000 
Injection 5n 5192081.60000 
Average 5188874.60000 
Standard Deviation 11420.7147 
Relative standard deviation 0.2201 
                 
 
 
 
 
 
TABLE – 45 
 
  Dissolution of Acetaminophen: 
 
SAMPLE 
NO AREA 
mg OF DRUG 
DISSOLVED 
% OF DRUG 
DISSOLVED 
1  490.037 98.00 
2  487.788 97.55 
3  481.464 97.89 
4  488.311 97.66 
5  488.896 97.77 
6  488.032 97.60 
 Average 488.75 97.75 
 Minimum 487.79 97.55 
 Maximum 490.04 98.00 
 Standard deviation 0.87 0.17 
 
Relative 
standard 
deviation 
0.18 0.17 
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TABLE – 46 
 
Calculation of Diphenhydramine. HCl: 
 No. of standard replicates: 
INJECTION Area 
Injection  1 215180.8000 
Injection 2 279951.8000 
Injection 3 267024.8000 
Injection 4 267012.8000 
Injection 5n 247081.8000 
Average 273178.80000 
Standard Deviation 2562.6933 
Related standard deviation 0.9381 
 
 
 
 
 
 
 
TABLE - 47 
 
Dissolution of Diphenhydramine HCl: 
 
 
Sample NO Area mg of drug Dissolved % of Drug Dissolved 
1  25.430                      101.72 
2  25.230 100.91 
3  25.333 101.33 
4  25.319 101.27 
5  25.216 100.86 
6  25.301 101.20 
 Average 25.30 101.202 
 Minimum 25.22                      100.86 
 Maximum 25.43 101.72 
 Standard 
deviation 
0.08 0.31 
 Relative 
standard 
deviation 
0.32 0.31 
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 DISSOLUTION PROFILE COMPARISON USING f1 f2 Factors: 
  TABLE-48 
Acetaminophen 
   f1,f2 calculation of Acetaminophen 
 
 
Result of Acetaminophen: 
  
 
 
 
 
 
 
 
 
 
 
 
Time(min) Rt Tt D = │Rt-Tt│ (Rt-Tt)2 
2 31.9 34.2 2.3 5.29 
4 67.3 69.7 2.4 5.76 
6 78.5 80.1 1.6 2.56 
10 82.0 84.3 2.3 5.29 
15 88.2 89.8 1.6 2.56 
20 89.4 92.6 3.2 10.24 
30 92.5 92.8 0.3 0.09 
45 95.5 98.6 3.1 9.61 
Total ∑ Rt = 625.3 ∑ Tt = 642.1 ∑ D = 16.8 ∑ (Rt-Tt)2 = 41.4
       Factors                    Standards              Obtained 
           f1                        0-15                    2.61 
           f2                      50-100                   93.6 
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                                                 TABLE:49 
Diphenhydramine Hydrochloride: 
                  f1,f2 calculation of Diphenhydramine Hydrochloride: 
 
 
Results of Diphenhydramine Hydrochloride: 
 
  Where:   
   f1=Dissimilarity factor,   f2=Similarity factor  
Rt and Tt are Test and Innovator cumulative percentage dissolution 
respectively at selected time points.   
 
   N= Number of time points 
• The assay  of Acetaminophen 500mg And Diphenhydramine Hydrochloride 
25mg tablets was within the  limit and complies with the specifications 
• The film coating process was also found to be smooth with no processing 
problems. 
• There is not much variation in the release of drug from the core and coated 
tablet. Indicating that the coating of tablets to obtain a 2.0% weight gain is 
found to be sufficient to coat the tablets.  
        
Time(min) Rt Tt D = │Rt-Tt│ (Rt-Tt)2 
2 19.3 22.8 3.5 12.25 
4 57.8 59.1 1.3 1.69 
6 72.4 73.6 1.2 1.44 
10 79.3 81.4 2.1 4.41 
15 84.5 86.3 1.8 3.24 
20 89.1 90.4 1.3 1.69 
30 92.7 93.8 1.1 1.21 
45 96.8 98.1 1.3 1.69 
Total ∑ Rt = 591.9 ∑ Tt = 605.5 ∑ D = 13.6 ∑ (Rt-Tt)2 = 27.62
       Factors                    Standards              Obtained 
           f1                        0-15                    2.24 
           f2                      50-100                   83.85 
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                                             TABLE – 50 
 
5.6 STABILITY DETAILS OF FORMULATION 11: 
 
 
Result→ 
     ↓ 
 
 
 
 
Stability  
Specifi-
cation 
      
400C/75
%RH 
   250C/6
0%RH 
  
 
Initial 30days 60bays 90days 30days 60day
s 
90day
s 
 
 
Description 
 
 
Blue 
colored, 
caplet 
shaped, film 
coated 
tablets with 
‘L751’ 
engraving 
on one side 
& plain on 
other side. 
Complies Complies Complies Compl
ies 
Compli
es 
comp
lies 
Comp
lies 
Moisture 
content 
% w/w 
 
NMT 3.0% 0.98 1.02 1.03 1.17 1.00 1.01 1.02 
%Drug 
release 
1.APAP 
 
2.Diphenhydr
amine.HCl 
 
 
NLT 85% 
of label 
claim in 30 
min. 
 
NLT 85% 
of label 
claim in 30 
min. 
101.8% 
 
 
 
           
94.1%        
99.7% 
 
 
 
 
  93.0% 
99.5%  
 
 
 
 
 93.5% 
99.1% 
 
 
 
 
 93.5% 
99.5%  
 
 
 
 
96.2% 
99.6
% 
 
 
 
 
 
96.4
% 
99.8
% 
 
 
 
96.5
% 
Assay % w/w 
 
1.APAP 
 
 
2.Diphen- 
hydramine 
Between 
95%-105% 
of label 
claim. 
 
 
101.% 
 
 
 
       
94.1% 
 
 
99.7% 
 
 
 
 
93.0% 
 
 
99.55 
 
 
 
 
93.5% 
 
 
95.1% 
 
 
 
 
93.7% 
 
 
96.4%     
 
 
 
 
 98.0% 
 
 
96.8
% 
 
 
 
 
98.4
% 
 
 
97.1
% 
 
 
 
98.7
% 
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Following results were observed after 3 months stability studies of Acetaminophen 500mg 
and Diphenhydramine Hydrochloride 25mg Tablets. 
 
1.  Description: The manufactured Acetaminophen 500mg and Diphenhydramine   
            Hydrochloride 25mg tablets are meeting the specification. 
 
2.  Identification: No change observed after 3 months storage. 
 
3.  Moisture content: Slight increase in moisture content of Acetaminophen 500mg and     
            Diphenhydramine Hydrochloride 25mg tablets were observed during 3     
            months storage at 40ºC/75% RH. 
 
4.  Dissolution: The tablets meet the specification criteria. 
 
5.  Related substance: The impurities or RS are well in the limits of the specification.           
 
6.  Assay: No significant change in assay of Acetaminophen 500mg and Diphenhydramine   
            Hydrochloride 25mg tablets was observed during 3 months storage at   
            40ºc/75% RH and 25ºc/60% RH. 
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FIGURE – 12 
 
STANDARD 
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FIGURE - 13 
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6. CONCLUSIONS 
 
• The main objective of this study was to develop and evaluate the formulation of 
Acetaminophen 500mg and Diphenhydramine Hydrochloride 25 mg tablets. 
• Several trials have been taken to optimize and develop a robust formulation. 
• Various processing problems were encountered during the formulation development and 
these were overcome with proper optimization of composition of formulation ingredients 
and processing conditions. 
• The reproducibility batch (T11) was taken for the finalized batch ie. T11 was charged for 
stability studies at accelerated and real time conditions.  
• The stability study for 3 months shows that the formulation is stable enough at 
400C/75%RH. 
• The formulation is a robust one and the performance is less likely to be affected by the 
various factors studied. The stability data is found to be satisfactory and so the scale up, 
Exhibit as well as validation batches can be planned for further progress. 
•  So it can be concluded that the Acetaminophen 500mg and Diphenhydramine-                     
hydrochloride 25mg tablets formulation T11 is robust and stable. 
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